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Summary 
Asthma is a global major health concern and it affects estimated 300 million people. The 
prevalence of asthma is rising and there is no cure for asthma, only the symptoms can be 
controlled. Acute asthma attacks are characterized by severe symptoms such as 
breathlessness, wheezing, tightness of the chest, and coughing, which may lead to 
hospitalization or death. Besides the acute symptoms, asthma is characterized by persistent 
airway inflammation and airway wall remodeling. The term airway wall remodeling 
summarizes the structural changes in the airway wall: epithelial cell shedding, goblet cell 
hyperplasia, hyperplasia and hypertrophy of the bronchial smooth muscle (BSM) bundles, 
basement membrane thickening and increased vascular density. Airway wall remodeling 
starts early in the pathogenesis of asthma and today it is suggested that remodeling is a 
prerequisite for other asthma pathologies. Furthermore, novel invasive therapies used to 
treat severe asthma provide evidence that the BSMC is a major effector cell in the 
pathology of asthma.  
In the present thesis novel mechanisms of BSMC regulation and their role in the induction 
of asthma-associated angiogenesis have been elucidated. Therefore, the differences in the 
angiogenic capacities of BSMC from asthma and non-asthma patients and their 
modification by different conditions, such as an (i) inflammatory microenvironment, (ii) 
the influence of low oxygen concentration, and (iii) the stimulation with the most potent 
asthma relevant allergen (house dust mite (HDM) allergen) on the angiogenic properties of 
BSMC have been studied.  
A major finding of this thesis is the increased angiogenic potential of BSMC from asthma 
patients and the altered release of CXCR2 ligands in an in vitro inflammatory environment. 
It has been demonstrated that BSMC from asthma patients release significantly more of the 
CXCR2 ligands ENA-78, GRO-α and IL-8, which may explain the increased vascular 
density in the sub-epithelial cell layers observed in the airways of asthma patients. These 
finding adds to previous studies showing that BSMC are a source of angiogenic factors 
(e.g. VEGF) and that CXCR2 ligands are elevated in the airway lining fluids of asthma 
patients. In this thesis BSMC have been shown to be a potential source of CXCR2 ligands, 
which induced spout outgrowth from endothelial cell spheroids in an in vitro model of 
angiogenesis.  
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Furthermore, this thesis investigated the effect of hypoxia on BSMC. Local restricted 
hypoxia in the airways of asthma patients had only recently been suggested. The animal 
model based hypothesis that hypoxia directly causes BSMC hyperplasia was tested. This 
hypothesis was not confirmed in human BSMC but nonetheless it was demonstrated that 
hypoxia leads to increased release of inflammatory and angiogenic mediators; as 
conditioned medium from BSMC grown under hypoxia induced angiogenesis in an in vitro 
model via VEGF. 
These findings suggest that different conditions or stimuli induce angiogenesis in asthma 
through different pathways and therefore, different therapeutic strategies might be needed.  
In the third part of this thesis the effect of HDM allergen on the release of inflammatory 
and angiogenic mediators from BSMC was assessed. Animal models demonstrated that 
exposure to HDM allergens increased airway wall vascularization. No direct contribution 
of BSMC to HDM extract induced angiogenesis was observed. However, HDM extract 
proteases degraded ENA-78, which is an import chemokine for neutrophil recruitment into 
the inflamed lung. Thus HDM allergens may alter the bio-availability of ENA-78 in the 
airways of asthma patients and modulate the immune response.  
 
The findings of this thesis add a small piece to the knowledge of asthma pathology, the 
mechanisms underlying airway wall remodeling and in particular BSMC hyperplasia and 
neovascularization. This might represent novel targets for treatment, especially for the 
prevention or reversal of airway wall remodeling.  
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General Introduction 
Asthma – a global health concern 
Definition 
Asthma is a complex, heterogeneous disease of unknown etiology. The disease is defined 
by its clinical, physiological and pathological features. Clinically asthma presents as 
recurrent episodes of wheezing, breathlessness, tightness of the chest, and coughing. These 
symptoms occur particularly but not solely during nighttime or in the early morning. The 
clinical spectrum of asthma is highly variable but all asthma patients suffer from airflow 
obstruction, which limits expiratory airflow. Pathological features in the lungs of asthma 
patients are the altered presence of immune cells in comparison to non-asthma patients as 
well as several functional alterations of the epithelium and the sub-epithelial cell layers 
including bronchial smooth muscle cells (BSMC). The pathology is usually referred to as 
airway inflammation and airway wall remodeling and will be addressed in detail in 
separate chapters. 
Due to the heterogeneous clinical manifestation, the unknown etiology, the variable 
responsiveness to treatments, and the variable long-term outcome the definition of asthma 
provided by the GINA (Global Initiative for Asthma) is descriptive, dealing with the 
functional consequences of this disease: 
“Asthma is a chronic inflammatory disorder of the airways in which many 
cells and cellular elements play a role. The chronic inflammation causes an 
associated increase in airway hyperresponsiveness that leads to recurrent 
episodes of wheezing, breathlessness, chest tightness, and coughing, 
particularly at night or in the early morning. These episodes are usually 
associated with widespread but variable airflow obstruction that is often 
reversible either spontaneously or with treatment.” 
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Prevalence and socio-economic impact 
In the mid-1980s asthma became a recognized public health concern in many countries. 
Population studies showed that asthma prevalence ranged from 8 –  20% in western 
countries and that the prevalence increased by 50% every decade [1]. This suggests that 
asthma is and will continue to be a major health concern. In 2004 Masoli et al. [2] and the 
GINA combined data from two studies [3-5] and reported a worldwide prevalence ranging 
from 0,7 (Macau) to 18,4% (Scotland) illustrated in Figure 1. A more recent study included 
about 180000 adults (aged 18 – 45y) in 70 countries [6]. This study revealed a worldwide 
prevalence of 4.3 – 8.6%, dependent on the stringency of definition criteria, with a highly 
variable prevalence across different countries. This was the first standardized, 
representative survey presented and currently is the best study that included population-
based data regarding respiratory symptoms and treatment. 
Figure 1: Worldwide prevalence of asthma. The highest prevalence of asthma (≥ 10.1% of total 
population) is found in North America, Peru and Brazil, the UK, Australia and New Zealand. [7]. 
The shortcoming of this study was that children, who represent more than 50% of all 
asthma patients, were not included. In children and young adults asthma is the most 
common chronic disorder. It is one of the major reasons for absence from school, loss of 
productivity, and responsible for vast health care costs [1, 8, 9]. In Europe asthma accounts 
for the majority of hospital admissions in children [10] and it appears that most children do 
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not “grow out of asthma” as it reappears in 30-50% of adults with a history of childhood 
asthma [11-13]. 
Undiagnosed, untreated or uncontrolled asthma has a severe impact on life quality and 
might be fatal [14]. Although the overall mortality rate of asthma is decreasing [2] a severe 
increase in the number of hospital admissions has been reported especially in children [15, 
16]. This may reflect not only an increase in the severity of asthma but also poor disease 
management and low socio-economic status.  
The economic costs caused by asthma exceed those of tuberculosis and HIV/AIDS 
combined (WHO factsheet 206: bronchial asthma) with an un-proportional contribution of 
severe asthma, which accounts for 10-20% of all cases but causes approximately 50% of 
all costs [16-19]. In addition to the economic burden, poorly controlled severe asthma 
causes work impairment, significant productivity losses and has a severe impact on social 
life [10, 20]. Diagnosis and treatment-availability is still challenging in resource-poor 
countries while the prevalence is rising sharply [1].  
A better understanding of the pathology of asthma as well as new treatment options are 
needed to reveal the underlying cause(s) of the disease and reasons for its increasing 
prevalence.  
Asthma phenotypes: Intrinsic vs. extrinsinc, atopic vs. non-atopic asthma, 
eosinophilic vs. neutrophilic  
Asthma is a heterogeneous disease with different clinical manifestations, variable inter-
individual severity of symptoms and degree of airflow obstruction, variable degrees of 
reversibility and loss of lung function, and variable responsiveness to therapy. Therefore, 
several approaches have been made to classify the different phenotypes of asthma. In 
general, those classifications provide the basis for clinicians to understand the 
characteristics of the disease in a patient in order to choose the right treatment. 
In the early 20
th
 century Rackemann was the first to sub-divide asthma into extrinsic and 
intrinsic asthma [21]. Intrinsic asthma is currently also known as atopic asthma and 
extrinsic asthma is synonymous with non-atopic asthma. Atopy, defined by increased 
levels of IgE is found in 60% of asthma patients [22, 23] and serum-IgE level correlated 
with asthma symptoms [24, 25]. To date the importance of atopy in childhood asthma is 
widely accepted, while its importance in adults has been questioned. A study analyzed the 
association of asthma and atopy and revealed only a weak and inconsistent association, 
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across populations as well as time periods [26]. The most important information from the 
classification as atopic or non-atopic asthma is in terms of disease onset and 
responsiveness to treatments. Atopic asthma has a peak of onset in children, whereas late-
onset asthma is mainly non-atopic. Patients with atopy normally respond better to 
glucocorticoid (GC)-treatment whereas a substantial number of patients with non-atopic 
asthma do not respond to GC or only to very high doses [27]. For research(ers) however 
this classification leaves several unanswered questions, in particular why only 7-10 % of 
all atopic people (40% of the population in developed countries) develop asthma [26, 28]. 
This indicates that atopy as a cause of asthma might have been overestimated.  
Additional classifications of asthma are based on asthma triggers such as: exercise-
induced, aspirin-induced, and allergen-induced asthma. 
The presence of distinct inflammatory cell types such as eosinophils or neutrophils in lung 
tissue or the airway lining fluids of asthmatic patients is another criterion to distinguish 
asthma phenotypes – eosinophilic and neutrophilic asthma. In mild asthma eosinophilic 
airway inflammation is present regardless of other characteristics such as atopy [29, 30]. 
Not all asthmatics display eosinophilia and some have an increased neutrophil number in 
the airways or airway lining fluids in absence of eosinophils [31-34]. Interestingly, 
neutrophilia has been linked to severe or fatal asthma [35, 36]. Furthermore it has been 
shown that most patients with non-eosinophilic asthma are non-atopic [27].  
As asthma phenotypes overlap, a novel approach to classify asthma is the cluster analysis. 
Haldar et al. [37] used data from 371 patients, recruited from primary and secondary care. 
Plotting the degree of eosinophilic inflammation against the severity of symptoms they 
identified four clearly distinct asthma phenotypes as shown in Figure 2. Together with the 
definition of the phenotype the authors also provide treatment guidelines in accordance to 
the different phenotypes  
  GENERAL INTRODUCTION 
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Figure 2 : Summary of asthma phenotypes identified by cluster analysis. Classification according 
symptom severity and observed inflammation reveals four asthma phenotypes (for details see text). Graph 
adapted from [38]. 
A second study using cluster analysis found similar phenotypes albeit different input 
parameters were used [39]. These two studies independently highlight the heterogeneity of 
the disease and the need for phenotype identification prior to start asthma therapy. 
Treatment with GC might have an influence on the above-mentioned classification as GC-
treated patients have reduced/no eosinophils and increased number of neutrophils [40]. 
Therefore, classification remains difficult and should preferably be done in naïve, untreated 
patients. 
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Asthma pathogenesis 
Asthma and airway inflammation 
Inflammation of the airway wall and the presence of immune cells in the lung tissue of 
asthma patients led to the classification of asthma as allergic hypersensitivity reactions of 
type I (acute asthma) and IV (chronic asthma). This view of asthma is usually referred to as 
the Th2-paradigm and was postulated several decades ago. It defines asthma as an 
immunological disorder, with Th2 cells as the pivotal immune cell to orchestrate, 
perpetuate and amplify chronic airway inflammation [41]. In this view chronic asthma 
develops as a result of an immune reaction driven by cytokines of the Interleukin (IL)-4 
gene cluster located on chromosome 5. The cluster is comprised of the genes coding for 
IL-3, IL-4, IL-5, IL-9, IL-12, IL-13, granulocyte macrophage colony-stimulating factor 
(GM-CSF), all of which are known to contribute to asthma by inducing the IgE-isotype-
switch of B cells, activation of mast cells, and proliferation and survival of eosinophils 
[42]. Mutations in this chromosomal region have been linked to atopy [43, 44]. The Th2-
paradigm may explain most of atopic/allergic inflammation but does not explain non-
atopic asthma. Furthermore, it does not explain early occurring airway wall remodeling. 
Figure 3 shows the major effector cells of the immune response / system, their localization, 
interactions with each other and resident tissue-forming cells and the most important 
mediators. 
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Figure 3: Airway wall inflammation (after allergen challenge). The most important effector cells of the 
innate and adaptive immune system and their mediators and the resident lung cells contributing to 
inflammation. [45]. 
Lymphocytes 
Lymphocytes are divided into two major subsets: T cells and B cells. Cells belonging to the 
T cell linage can be either CD8
+
 (cytotoxic T cells) or CD4
+
 (T helper cells). The major 
function of cytotoxic T cells is the clearance of infected/dysfunctional somatic cells and 
therefore, they have only little contribution to asthma pathology. The contribution of B 
cells to airway inflammation is mainly by the production of IgE (in response to IL-4 
stimulation), which is a major mediator in atopic asthma.  
A better understanding of the underlying immunological mechanisms of airway 
inflammation came from the discovery of two distinct T helper cell subsets: Th1 and Th2 
cells. In rodent models of airway inflammation, Th2 cells were the dominating cell type in 
the lung tissue [46]. Th2 cells dominated airway inflammation was also observed in the 
airways of humans suffering from asthma [24]. The predilection towards a Th2-mediated 
immune response including the Th2 cytokine profile in asthma can explain the observed 
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eosinophilic inflammation and/or the overproduction of IgE by B cells [47]. Cytokines of 
the Th2 panel have various effects and act on several target cells. IL-4 is an important 
cytokine released from Th2 cells. It acts in a positive feedback loop on Th2 cells and is, 
together with IL-13, crucial for initiation of the isotype switch in B cells. IL-3, IL-5 and 
GM-CSF are essential for the proliferation and maturation of eosinophils.  
Recently a third subset of T helper cells was defined: Th17 cells. Like Th1 and Th2 cells, 
Th17 cells belong to the CD4
+
 T cell subset. They are named after their major cytokine: IL-
17, which induces cytokine and chemokine release from bronchial epithelial cells, vein 
endothelial cells, fibroblasts and eosinophils and thereby influences recruitment of 
monocytes and neutrophils to inflamed tissue. IL-17 was upregulated in lungs of asthmatic 
patients and was linked to disease severity [48, 49]. In bronchial biopsies of asthmatics 
increased numbers of Th17 cells were reported [50] but the contribution of Th17 cells to 
asthma pathogenesis requires further investigation.  
Another CD4
+ 
T
 
cell subset, regulatory T cells CD4
+
/CD25
+
 (Treg), is implicated in asthma. 
The function of Treg is the mediation of the immune tolerance and the prevention of 
immune responses towards harmless antigens and host responses to (auto-) antigens. Still, 
the data on Treg in asthma are controversial and incomplete, but recent in vitro studies 
suggest an important role of Treg in asthma. It was shown that Treg in asthmatic patients 
decreased and presence of Treg could be positively correlated with the FEV1 (forced 
expiratory volume in 1 s) [51, 52].  
It was demonstrated that an appropriate Th1/Th2-balance prevented Th2-driven 
inflammation [53] and Tregs can suppress exaggerated Th2 responses via IL-10 [54]. This 
led to the hypothesis that Th2-driven diseases like atopic asthma can be either caused by an 
increase in Th2 cells (with the resulting decrease in Th1) or a decrease of Treg cells.  
Lymphocytes do no only mediated acute and chronic inflammation but are also involved in 
angiogenesis [55, 56]. Angiogenesis, as well as inflammation involves a complex network 
of mediators and cellular interactions. In a murine model of airway remodeling it was 
demonstrated that mice lacking B cells had significantly reduced angiogenesis [57]. 
Furthermore, many of the cytokines released by T cells are implicated in angiogenesis as 
well. Angiogenesis-related cytokines of the Th1 profile are mainly anti-angiogenic [56] 
whereas many Th2 cytokines (IL-4, IL-6, IL-13) promote angiogenesis. IL-17 has been 
shown to promote angiogenesis in a murine model of breast cancer [58] and might be also 
involved in remodeling in asthma. The induction of angiogenesis can be mediated directly 
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by the release of mediators involved in endothelial cell (EC) survival, migration, 
proliferation, apoptosis or indirectly by inducing the release of cytokines and modulate 
receptor expression on target cells [56] 
Myeloid Cells 
Several cell types of the innate immune system are recognized to contribute to asthma 
pathogenesis. Mast cells are located in all vascularized tissues but most prominently in 
tissues forming interfaces with the environment, e.g. the lung. In normal human bronchi 
mast cells are located in the submucosal connective tissues. In asthmatics, additional mast 
cells are found within the bronchial smooth muscle bundles and in the epithelium. This 
pathology seems to be specific for asthma, since these mast cells are not found in other 
inflammatory pulmonary diseases [29, 59, 60]. In allergic asthmatics, mast cells are highly 
responsive to inhaled allergens [61, 62]. Allergen-bound IgE crosslinks IgE-receptors 
expressed on the mast cell surface and this is the trigger for the release of preformed 
granules containing histamine, several proteases (amongst others chymase and tryptase), 
heparin and some pro-inflammatory and angiogenic cytokines (TNF-, IL-4, IL-5) [55, 63-
69]. Mast cells cause the contraction of BSMC and increased microvascular permeability 
leading to edema through the production of eicosanoids and the release of histamine [70]. 
Mast cell-derived mediators account for the so-called early or immediate response to 
allergens and for the late response by recruitment of other immune cells and perpetuation 
of a Th2-like airway inflammation [71]. Many of the mediators released from mast cells 
also promote angiogenesis and thus, mast cells are an important link between inflammation 
and angiogenesis [55, 67, 68]. 
Neutrophils and eosinophils are the best-studied polymorphonuclear granulocytes in 
asthma. Similar to mast cells they contain granules with preformed mediators [72, 73]. 
Eosinophils are recruited to sites of inflammation by cytokines, chemokines and lipid 
mediators (e.g. IL-3, GMC-SF, eotaxin 1-3, monocyte chemotactic protein (MCP)-3, MCP-
4, prostaglandin (PGD) 2, leukotrien B (LTB) 4) and complete their maturation after 
stimulation with IL-5 [74-76]. In many asthmatics it was shown that the eosinophil number 
in the airways or airway lining fluids is elevated [34, 77, 78] and that treatment with GC 
significantly reduced their number [79, 80]. Eosinophils have long been regarded as key 
effector cells in asthma but their role in mediating the disease has been challenged [81]. 
Nonetheless, eosinophils are known be pro-angiogenic by the release of several cytokines 
such as vascular endothelial cell growth factor (VEGF)-A, fibroblast growth factor (FGF)-
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2, tumor necrosis factor (TNF)-α, GM-CSF, neurite growth factor (NGF), and IL-8 and 
might therefore contribute to the remodeling process in asthma pathology [82, 83].  
Neutrophils are the most abundant type of white blood cells and effector cells in the innate 
immune response. They are the first cells recruited to the site of inflammation during the 
acute phase of the immune reaction. It has been reported that the number of activated 
neutrophils in symptomatic severe asthmatics is elevated [31, 84]. Although some studies 
reported elevated numbers of neutrophils in bronchoalveolar lavage fluid (BALF) of mild 
asthmatics [85, 86], others were not able to confirm these findings [87]. Additional 
research demonstrated increased numbers of neutrophils only in non-atopic asthmatics, 
whereas the number of neutrophils in atopic asthmatics was not elevated [88]. 
Neutrophils do not release cys-leukotriens, major basic protein (MBP) or cytokines of the 
Th2 profile, nor do they contribute to eosinophilic inflammation directly. Still they are a 
source of several mediators, which modify the eosinophilic response [89]. Furthermore, 
neutrophils are a source of important angiogenic factors such as VEGF, IL-8, TNF-α, 
hepatocyte growth factor (HGF) and matrix metalloproteases [90-92]. Evidence for the 
implication of polymorphonuclear granulocytes in angiogenesis and tissue remodeling was 
provided in an animal model with impaired angiogenesis and wound healing after blocking 
neutrophil recruitment [93, 94]. 
The role of neutrophils in asthma requires further investigations, as treatment with inhaled 
GC is less effective in patients with neutrophilic inflammation compared to patients with 
eosinophilic inflammation [27].  
 
In conclusion, these data shows that several immune cells play a role in airway 
inflammation in asthma and that those cells can also contribute to angiogenesis. The 
recruitment of a multitude of immune cells (mast cells, basophils, eosinophils, 
macrophages and lymphocytes) is a hallmark of the asthmatic lung.  
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Airway wall remodeling in asthma 
The first described pathology of asthma was the thickening of the airway wall [95]. The 
increased thickness of the airway walls is caused by alterations of several airway wall 
forming tissues and some studies found correlations with disease severity [96-98]. The 
most striking features of airway wall remodeling are: epithelial cell shedding and 
thickening, goblet cell hyperplasia, mucus gland hypertrophy, basement membrane 
thickening, hyperplasia and hypertrophy of BSMC, and increased vascularization [67, 99-
102]. Figure 4 illustrates the alterations of the remodeled airway wall in asthma patients. 
The aberrant behavior of mesenchymal cells is crucial to understand the pathology of 
asthma and this hypothesis is almost 100 years old [95]. However, this hypothesis became 
less important after eosinophilia was observed in asthmatic lungs and as the Th2-paradigm 
arose. Thus, in the past 25 years the research and the treatment of asthma were carried out 
with a focus on the allergic component of this disease. Although the Th2-paradigm is still 
important, it is acknowledged that non-Th2 immune cells and resident cells of the lung are 
important to develop asthma [103]. It is recognized that many celltypes (like epithelial 
cells, lung fibroblasts or BSMC) are sources of “asthma-determining” Th2 cytokines such 
as IL-4, IL5, IL-9, IL-13 [104-107]. Today, it is again a matter of debate whether the 
immune system is the key player of asthma pathogenesis, or if the disease originates within 
the lung itself [108]. The hypothesis that tissue-forming lung cells induce asthma is 
strengthened by the fact that airway wall remodeling is observed in preschool children 
without clinical signs of inflammation [109-116]. Remodeling of the airway wall 
contributes to the hallmark feature of asthma - the airflow obstruction- in a fixed manner. 
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Figure 4: Alteration of the airway walls of healthy (a-c) and asthmatic (d-f) subjects. Tissue sectioned stained with 
haematoxylin and eosin (a and d), periodic acid–Schiff with diastase (b and e), or pinacyanol erythrosinate (c and f). 
Scale bars: 500 µm (a and d), 100 µm (insets a, b, d, e and c and f), 400 µm (b and e). In the normal bronchus are few 
goblet cells (black arrows) in the epithelium. The basement membrane and underlying lamina reticularis (*

in a) is 
hardly visible. The submucosa (double-headed arrow) in a) contains few leukocytes and mast cells (blue arrows in c). 
Few adjacent mast cells (red arrow in c) are found in the smooth muscle (SM). d–f, In the bronchus of the asthma patient 
the airway lumen is filled with mucus (M) (d and e). There are many goblet cells (black arrows in insets) and intra-
epithelial mast cell (black arrows in f). The lamina reticularis (* in d) is markedly thickened and thus visible. Many 
eosinophils and other leukocytes (green arrows in inset in d) as well as mast cells (blue arrows in f) are found in the 
submucosa (double-headed arrows in d). The layer of BSM is thickened with an increased number of mast cells (red 
arrows in f). (Figure courtesy of G. J. Berry, Stanford University, California.). [45]  
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Airway wall remodeling includes both, inflammatory cells and tissue-forming cells of the 
lung. Both celltypes considerably contribute to airway wall remodeling in asthma. 
Furthermore, it is clear that some cells of the immune system have various functions in the 
pathogenesis of asthma. In the following, the potential role of immune cells and tissue-
forming lung cells in the process of airway wall remodeling is described:  
Immune Cells 
Connective tissue mast cells 
In asthma the number of connective tissue mast cells in deeper regions of the lung is 
markedly increased and they might be involved in “programming” the adjacent BSMC of 
asthmatics [59, 64, 117-119]. In contrast to the mast cells of the submucosa and the 
epithelium, the mast cells within the BSM bundles are always tryptase and chymase 
positive (MCTC) and their number has been linked to the severity of asthma [120] and 
airway hyperresponsiveness [59]. Mast cells are known to be one of the major sources of 
pro-angiogenic factors and the number of tryptase-positive mast cells has been correlated 
with angiogenesis in human endometrial cancer [121]. Recent studies suggested a role of 
mast cells in the vascular component of airway wall remodeling in asthma [122, 123]. 
Eosinophils 
As mentioned in chapters before eosinophils have long been regarded the most important 
immunomodulatory cell in asthma. Eosinophils are also important in airway wall 
remodeling, demonstrated by the finding that eosinophil-depletion caused altered 
composition of the basement membrane and therefore eosinophils might have more 
influence on remodeling then assumed so far [124, 125]. Furthermore, eosinophils produce 
TGF-β1 and thereby promote proliferation of fibroblasts, myo-fibroblast maturation and 
collagen synthesis [126]. Eosinophils are the source of many angiogenic factors [127, 128] 
and can therefore induce angiogenesis in the asthmatic lung. All these findings suggest 
multiple functions of eosinophils in asthma pathogenesis. 
These findings illustrate the interconnection of the immune system, inflammation and 
resident lung cells in the pathology of asthma.  
Resident, tissue-forming lung cells 
Before the discovery that asthma is not always associated with eosinophilia and/or Th2 cell 
accumulation, the disease was mainly regarded as an immunological disorder. The 
observation that tissue-forming lung cells also produce mediators of inflammation and 
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cytokines prompted asthma researcher to rethink the role of tissue-forming lung cells in the 
pathogenesis of asthma.  
Epithelial cells  
Epithelial cells were considered merely a mechanical barrier protecting the body from the 
environment. It is the first line barrier against all influences from outside (allergens, 
pollutants, temperature, etc.) and has been reported to be damaged and metaplastic 
(pseudostratisfied) in asthma. Epithelial cells produce a vast spectrum of cytokines and 
chemokines [129, 130]. It has been shown that epithelial cell proliferation in asthmatics is 
impaired, which was attributed to altered level of several markers of proliferation such as 
proliferating cell nuclear antigen (PCNA), Ki67, and p21wat [131-133]. These findings 
suggest a chronic injury with reduced ability to repair [133]. The composition of the 
extracellular matrix (forming hemi-desmosomes with the epithelial cells) is altered and the 
expression of tight-junction proteins is reduced in asthmatics [134-136]. This might be 
causative for the epithelium in asthmatics to display an increased sensitivity to oxidant 
pollution like ozone, tobacco smoke, or ambient air pollution [137].  
The impaired proliferation of cells forming a frequently renewing tissue and the impaired 
mechanical properties of the epithelium, as it occurs in the airways of asthmatics, might 
lead to the production of a variety of cytokines and chemokines reminiscent of chronic 
wound healing [133]. Several studies demonstrated the altered expression and secretion of 
chemokines and cytokines by airway epithelial cells from asthmatics compared to controls 
[138, 139]. 
The airway epithelium is a source of mediators of inflammation and remodeling (including 
angiogenesis), its shedding might enable allergens to access the lung tissue, and the 
metaplasia of the mucus producing cells directly causes airflow limitations.  
Bronchial smooth muscle cells 
The most obvious feature of airway wall remodeling in asthma is related to the BSM. A 
marked increase in BSM mass is observed in the asthmatic airway wall, which is due to 
hyperplasia and hypertrophy of BSMC.  
Over the past 20-25 years the view on BSMC and their role in the pathology of asthma has 
significantly changed. Bronchoconstriction is the most severe symptom of an asthma attack 
and the cells of the BSM are the major effector cells and the proximal cause of the 
excessive airway narrowing [140]. The constriction it is completely or partially reversible, 
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but sometimes only with the help of bronchodilating drugs. The two characteristics of 
BSMC that contribute to bronchoconstriction in asthma patients are summarized as airway 
hyperresponsiveness (AHR) [141]. One characteristic is airway hypersensitivity, which 
describes the response of BSMC of asthma patients to low doses of stimuli. The other 
alteration of BSM is airway hyperreactivity, which describes an abnormal strong 
bronchoconstrictive response. The reason for AHR remains unclear, but it is suggested that 
it is due to fundamental changes within the muscle cell itself, due to external changes (e.g. 
reduced mechanical load) or a combination of both. In vitro, the maximal shortening of 
smooth muscles is approximately 70% of the optimal length. In a physiological context the 
contraction of a muscle is abrogated as soon as there is a balance between the contractile 
force of the muscle and the load against which the muscle contracts. The load-setting 
factors are the elasticity of the airway wall, the tethering forces of the lung-parenchyma 
and other contractile cells. 
The active and passive forces limit the narrowing of the airways in healthy individuals 
even upon challenge and breathing remains easy. In asthmatics the muscle itself is not 
stronger, but the BSM is hyperplastic and hypertrophic [142, 143]. Due to this pathology 
the contraction might occur faster rather than stronger compared to healthy individuals and 
the relaxation might be impaired [144, 145]. 
The increase in BSM mass has been observed in young adults (17-23y) [146] and in 
children without any signs of eosinophilic inflammation [111, 147]. These observations 
suggest that the increased BSM mass is rather the cause of asthma then a consequence of 
progressing disease. Besides their effector role in bronchoconstriction BSMC are 
synthetically active cells, which are able to produce a variety of inflammatory and 
angiogenic mediators such as: GM-CSF, IL-1β, IL-2, IL-5, IL-6, IL-8, IL-11, IL10, 
Eotaxin, bFGF, PDGF-BB and VEGF [148]. It has been show that BSMC of asthmatics 
respond differentially (quantitatively and qualitatively) compared to healthy subjects. For 
instances, BSMC of asthmatics release more IL-6 and IL-8 after stimulation with house 
dust mite (HDM) extracts or after rhinovirus (RV) infection [149, 150].  
The release of many of the aforementioned cytokines can be induced by several stimuli or 
in paracrine and autocrine regulated mechanisms. This shows that tissue-forming cells of 
the airways provide a mechanism how inflammation may be amplified and/or perpetuated 
without the involvement of immune cells.  
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In addition, BSMC are an important source of extracellular matrix (ECM) components. It 
has been demonstrated that serum derived from asthma patients leads to increased 
generation of fibronectin, lamin γ, and proteoglycans from BSMC [151-153]. BSMC from 
asthmatics also produce more connective tissue growth factor (CTGF), which may further 
contribute to the alterations of the basement membrane (described in the following chapter) 
[154, 155]. 
These findings identified BSMC as attractive and promising targets in airway biology 
research. Moreover, the interaction and interconnection of BSMC and immune cells and of 
BSMC and ECM components highlight the strong interdependence of the systems 
discussed in this chapter. Insights into disease specific alterations might open the door for 
new therapeutics. 
ECM/Basement membrane thickening 
When airway remodeling was reported for the first time a thickening of the basement 
membrane (BM) was described [95]. Decades after this first description of BM thickening 
electron-microscopy revealed that the thickened layer is not the BM itself but a zone 
adjacent to it – the lamina reticularis [156]. Since most publications call this phenomenon 
“basement/basal membrane thickening” this term will be used throughout this thesis.  
Several studies demonstrated that the BM is thickened, even in young asthmatic children 
and this thickening is comparable to that observed in adults [114, 134, 157, 158]. In non-
diseased subjects the BM is 4-5 µm thick, whereas in asthmatics it varies between 7 and 23 
µm [159]. Among chronic inflammatory lung diseases, which are also accompanied by 
ECM alterations (like cystic fibrosis or chronic obstructive pulmonary disease (COPD)) 
BM thickening (including alterations in dimension and composition) is a unique pathology 
of asthma [160]. The thickening of the BM has also impact on the efficacy of treatment, as 
it was correlated with a limited short-term responsiveness to GC treatment [161]. 
There are multiple processes and cell types, which potentially contribute to the increased 
and/or altered deposition of ECM components in the BM. As mentioned earlier BSMC 
produce a variety of ECM components. In asthma, the ECM deposition is increased and 
BSMC mass correlates with BM thickening. This indicates that alterations in ECM 
composition and subsequent BM thickening may also be BSMC dependent [162]. 
Furthermore, the ECM is a reservoir for secreted factors, which can be released upon 
degradation/reconstruction of the ECM within the tissue. VEGF, for instance binds to the 
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ECM through heparan sulphate proteoglycans and is released upon matrix degradation 
processes [163, 164]. 
Taken together, these findings illustrate the importance of tissue-forming cells in 
perpetuating and amplifying airway inflammation and airway wall remodeling. Therefore, 
asthma should not be solely regarded as an inflammatory disease, but rather as a complex 
disease where alterations of the microenvironment and cellular structure lead to airway 
inflammation and airway wall remodeling. Resident tissue-forming lung cells are 
important target cells as potential drug targets, biomarkers, or for the assessment of therapy 
efficacy [165, 166]. 
 
In summary, airway wall remodeling is a key feature of asthma and its occurrence in very 
young patients [114, 134, 158] suggests it to be a necessary precursor to the onset of 
asthma [109, 111, 112, 116, 167-170]. 
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Environmental factors in asthma 
Asthma is a complex, multi-factorial disease and the diseases development depends on 
genetic pre-deposition as well as environmental factors. Environmental factors have a 
crucial role as cause and as triggers of asthma(-exacerbations). A considerable overlap 
between environmental factors that cause asthma and influence the development of asthma 
exists. Nonetheless causative factors cannot always be identified in a patient nor can 
causative and triggering factors be equated. 
Allergens 
Allergens are complex, biochemically active molecules including enzymes, enzyme 
inhibitors and proteins involved in molecular transport, regulation and cell and tissue 
structure. They are recognized by the immune system and provoke an immune response 
although they are harmless. Among the different classes of allergens, ingestionallergens 
and most importantly aeroallergens contribute to the development of asthma and asthma 
exacerbation. Food allergies have been implicated in the development of asthma [171] and 
peanuts or seafood might cause asthma symptoms in allergic subjects [23]. Exposure to 
indoor and outdoor allergens (HDM, cockroach, cat and dog dander, pollen or fungal 
spores) early in life was shown to play a considerable role in the development of asthma 
[172, 173]. Furthermore it was demonstrated that inhalation of allergens can cause 
bronchoconstriction and, as allergens are ubiquitously present they also contribute to 
airway wall remodeling. Torrego et al. showed that allergen challenge of atopic asthmatics 
results in altered composition of the basement membrane, increase of eosinophils and 
neutrophils, and an altered release of TGFβ1/2 [139]. In rodent models of allergic asthma it 
was demonstrated that repeated allergen-challenge results in increased release of pro-
inflammatory mediators as well as (vascular) remodeling [174-179]. Doyle et al. show that 
the microvascular density in mice is increased after allergen-challenge and that this is in 
part due to the release of angiogenic mediators from vascular endothelial progenitor cells 
[180]. These findings are in accordance with another study revealing increased number and 
diameter of vessels in endobronchial biopsies of asthmatics after allergen challenge [181]. 
In Europe the most important aeroallergen are allergens derived from house dust mites 
(HDM). Common house dust comprises of 13 different species of HDM. The major 
sources of allergens are three different HDM species: the European house dust mite 
(Dermatophagoides pteronyssinus), the American house dust mite (Dermatophagoides 
farinae) and a third species Euroglyphus maynei [182-184]. The species D. pteronyssinus 
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and D. farinae are predominating and they coexist in most geographical regions [185]. 
About 50% of allergic adults and 80% of allergic children are sensitized against HDM-
derived allergens and HDM allergens are a major trigger of asthma exacerbation [186]. 
HDM-derived allergens are the mites themselves (in all stages of development) and most 
importantly their fecal pellets, which contain the majority of immunogenic compounds 
[187]. The mode of action how HDM allergens contribute to the development of asthma 
and acute asthma attacks are incompletely understood yet. This in part due to the fact, that 
HDM extracts contain of a pleiotropy of different proteins and more than 20 of them were 
identified to induce IgE-mediated immune reactions [188]. Although all HDM-derived 
allergens have IgE-binding capacities, the absorption of IgE from sera of allergic subjects 
varies highly between the different proteins. Der p1 and p2 absorb 50% of IgE and Der p4, 
p5 and p6 absorb another 30% of the IgE present in the sera [189].  
Besides the immunogenicity of the HDM-derived proteins they have also enzymatic 
functions, which can affect the immune/tissue response. Protease activity is a common 
feature of many allergens (fungi, animal dander, pollen). In HDM extracts the cysteine 
protease Der p1 cleaves epithelial tight junctions and thereby opens the door for the 
allergens to penetrate into the tissue [190]. This allows an uptake and processing of the 
HDM-derived proteins by tissue-resident dendritic cells. A recent study provided evidence 
that the impaired epithelial barrier is crucial for HDM-mediated pathological features of 
asthma (eosinophilic inflammation, goblet cell hyperplasia and AHR) but that this can be 
mediated independently from Ser- and Cys-protease activity [191]. It is reasonable that 
cleavage of tight junctions will also allow protein delivery to tissue-forming cells like 
BSMC. The proteases do not only have a direct effect by cleavage of tight junctions-
forming proteins but they can also activate protease-activated receptors (PAR), which leads 
to lymphocyte infiltration to the airways [192] and results in BSMC contraction and 
proliferation [149, 193].  
HDM extract challenge in a sheep model of chronic asthma increased the vascular density 
in the lungs in response to the stimulus. Furthermore, this study provided evidence of a 
direct correlation of airway wall vascularity and thickness revealing a direct link between 
angiogenesis and remodeling [194].  
In order to study the effects of HDM in in vitro and in vivo systems aqueous solutions of 
95% house dust mites (in all developmental stages) and 5% fecal pellets or 
purified/chemically synthesized Der p or Der f proteins are used. The use of purified 
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proteins elicits very specific functions and effects, but in daily life patients are exposed to 
the complete mixture of immunogenic, proteolytic and several other proteins. Therefore, 
the use of total HDM extract might reflect better the contribution of HDM allergens to the 
pathogenesis of asthma. 
Pathogens 
A considerable overlap between the aforementioned allergens, their implication in asthma 
pathogenesis, and the pathogens discussed in this chapter exists. LPS and endotoxins 
detected in whole HDM extracts are derived from bacteria of the Bartonella species [195]. 
A recent study provided evidence that recurrent wheezing in young children was associated 
with bacterial infections [196] and bacterial infections of the lower respiratory tract in 
asthmatics have been linked to symptom frequency and severity [197]. Despite the fact that 
several studies demonstrated the implication of bacterial infections in the pathogenesis of 
asthma it is not yet clear how bacterial infection influence the disease. Initiation of the 
innate immune response by activation of toll-like receptors (TLR) followed by the release 
of pro-inflammatory cytokines is one possible mechanism. Another possible mechanism is 
the release of TGF-β induced by bacterial LPS. Increased concentrations of TGF-β can 
activate fibroblasts and thereby induce an increased production of ECM proteins, which 
causes airway wall thickening.  
Several different viruses have been associated with the development of asthma or asthma 
exacerbation [198]. Viral infections during early childhood have been identified as risk 
factors to develop asthma later in life [199, 200]. Furthermore, it has been shown that 
infections of human epithelial cells and fibroblasts with RV caused the release of pro-
angiogenic and remodeling mediators from these cell-types and thereby caused 
angiogenesis in vitro [201, 202]. Although it is not fully understood yet how viral 
infections and development of asthma or asthma exacerbation are linked the results of 
several studies suggest that viral infections are not a cause of asthma per se, but rather 
suggest a susceptibility to both, viral infections and asthma. The tissue damage due to viral 
clearance is supposed to cause an environmental injury, which in turn alters the epithelial 
cells and thereby causes inflammation and at a later stage remodeling.  
A third group of pathogens are fungi. A recent study identified 3 different fungi to play 
important role in the pathology of asthma (Aspergillus, Cladosporium, Alternia). This 
study provides evidence that exposure to indoor fungal spores is worsening asthma 
symptoms, whereas exposure to outdoor occurring spores led to symptom impairment 
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[203]. Due to their allergic potential fungal spores also belong to the extrinsic factors 
mentioned before. 
Others 
Besides the aforementioned factors, several other, naturally occurring stimuli can induce 
asthma and/or cause asthma exacerbations/attacks. Cold air, exercise, ozone, tobacco 
smoke or exhaust fumes are only some of those stimuli and the mechanisms how they 
cause bronchoconstriction are mainly unrevealed yet. The existance of many different 
provoking agents/circumstances further illustrates the complexity of the disease and the 
constant and/or unavoidable exposure to many of them highlights the need for new 
treatment options and curative drugs.  
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Genetics of asthma 
Asthma is a heterogeneous disease with a variety of clinical manifestations and unknown 
etiology. Several approaches have been made to identify asthma susceptibility genes or the 
genetic background for the disease. Asthma could not be linked to a single gene or to a 
distinct chromosomal region. Rather, genetic studies confirm asthma to be a complex 
disorder. The use of genome wide associated studies (GWAS) contributed significantly to 
the identification of several candidate genes. In GWAS many single nucleotide 
polymorphisms (SNP) are compared hypothesis-free across the entire genome. The 
candidate genes identified by several GWAS and other types of genetic studies (candidate 
gene association studies and genome-wide linkage studies) can be divided into four groups: 
The first group includes genes that encode proteins to sustain epithelial barrier function 
[204-206]. The second group is comprised of genes encoding proteins involved 
environmental sensing and immune detection [207-211]. Genes encoding proteins of the 
Th2 mediated response and recruitment of eosinophils are represented in group three [42, 
43, 208, 210, 212-216] and genes encoding proteins implicated in the tissue response are 
filed in group four [217-219].  
A disintegrin and metalloprotease (ADAM)-33, a gene of group IV has been identified as 
an asthma susceptibility gene in several studies [217, 218, 220]. A recent study focused on 
function of ADAM-33 in airway wall remodeling in the asthmatic lung. It was 
demonstrated that soluble ADAM-33 can promote angiogenesis and that this effect is 
enhanced by environmental factors causing epithelial damage [221]. In the scope of 
angiogenesis-related genes SNP in the VEGF gene were identified related to atopy and 
asthma [222-225].  
The effect of a single gene variant seems to be small and therefore suggest a complex 
network between interaction/combination of multiple genetic variants, environmental 
factors and epigenetic regulations [226]. Therefore, it is important to keep in mind that the 
aim of genetic studies is to identify groups/combinations of variants that reliably predict 
the risk of susceptibility and/or severity. Furthermore, it is important to consider the 
influence of environmental factors for the onset and progression of asthma.  
In summary the development and exacerbation of asthma is a complex, multifactorial 
process, which involves genetic predisposition, epigenetic mechanism as well as 
environmental factors.   
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Angiogenesis  
General 
Angiogenesis is the process of blood vessel formation from existing vessels and 
angiogenesis depends on the balance of positive and negative modulators. During 
adolescence angiogenesis occurs in physiologically growing organs but in normal tissues in 
adults, vascular quiescence is mediated [227]. Nonetheless, quiescent endothelial cells 
(EC) remain their capacity to proliferate, migrate and synthesize pro-angiogenic factors 
and are thereby able to form new blood vessels if required or induced during pathogenesis 
of diseases. In healthy subjects the formation of blood vessels occurs only in the female 
reproductive cycle [228, 229]. Apart from that, angiogenesis is induced in wound healing 
after injury. It also occurs in diseases like rheumatoid arthritis (RA), solid tumors, and in 
chronic airway diseases such as asthma, COPD or bronchiolitis obliterans syndrome 
(BOS). In diseases associated with a pathological increase in vasculature, the net balance is 
shifted towards pro-angiogenic factors. This can be achieved through a reduction of 
angiostatic factors, the increase of angiogenic factors or a combination of both. 
The formation of new blood vessels is a complex process involving multiple factors that 
either promote (angiogenic) or counteract/inhibit (angiostatic) angiogenesis. Mediators 
involved in the regulation of angiogenesis come from seven classes of molecules (Figure 
5). VEGF, angiopoietin-1 (Ang-1), bFGF, TGF-β, PDGF; TNF-α are amongst the best 
studied angiogenic proteins [230, 231]. More recent studies showed that a so far not 
noticed class of molecules is also involved in the formation of new blood vessels - 
chemokines and their receptors. Chemokines are small (8 - 12 kDA) proteins that attract 
circulating immune cells to sites of inflammation/injury. They were first identified in 1977 
with the purification of CXCL4 [232] and comprise to date of more than 50 members 
divided into 4 families (in regard to conserved cysteine-residues): C-, CC-, CXC-, and 
CX2C-chemokines [233]. In contrast to other cytokines, all chemokines are signaling via G 
protein coupled receptors (GPCR). Based on the sequence of the amino acids the 
angiogenesis-related chemokines are either of the CC-[234] or of the CXC-[235-237] 
family of chemokines. The CXC-chemokines are further divided into chemokines with or 
without a conserved amino acid-sequence Glu-Leu-Arg (ELR) – the ELR+ and ELR—
chemokines. Among those, ELR
+
-chemokines are in favor to promote angiogenesis 
whereas ELR
-
-chemokines inhibit it. ELR
+
-chemokines are signaling via one of two 
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receptors CXCR1 and CXCR2 but mediate their angiogenic effects through CXCR2 [238-
240]. 
 
Figure 5: Classes of molecules involved in the regulation of angiogenesis. From [241] 
The implication of CXC-chemokine and their corresponding receptor in neovascularization 
has been mainly described in the context of cancer. It has a critical role in the progression 
of many cancers including breast cancer, bronchogenic carcinomas, malignancies of the 
gastrointestinal tract, prostate cancer, ovarian cancer, glioblastoma as well as head and 
neck cancer [242-247]. Furthermore, it has been shown the CXC-chemokines are involved 
in several lung diseases, which involve altered angiogenesis such as idiopathic pulmonary 
fibrosis (IPF), BOS or acute respiratory distress syndrome (ARDS) [248-250].   
  GENERAL INTRODUCTION 
27 
Angiogenesis in asthma 
Airway wall remodeling in asthma comprises of several features of which one is 
angiogenesis. The first incidence that vascular alterations occur in the airways of asthma 
patients was published in 1960. Besides other features of airway wall remodeling, Dunhill 
reported the dilatation of blood vessels in lung tissue from asthma patients [251]. It has 
been shown ex vivo as well as in vivo that the sub-epithelial layers of the lungs of asthmatic 
patients exhibit an increased vascular density [134, 252-254]. Besides the increased 
vascular density other prominent alterations of the bronchial vasculature have been 
described. Several studies in humans and in animal models of asthma show that the blood 
flow in the asthmatic lung is increased [255-258]. Furthermore, not only the vessel number 
is increased in asthmatics it has also been also demonstrated that the vasculature in 
asthmatics is more permeable, which in turn led to edema [259]. The increased 
permeability of vessels has another important effect. Vessel leakage is an important 
prerequisite for tissue inflammation, as the extravasation of inflammatory cells to the tissue 
requires transmigration through the endothelium. 
To date the factors and mechanisms that induce angiogenesis in the airways of asthma 
patients are not fully understood. Recent studies were able to provide evidence that VEGF 
is an important factor in mediating angiogenesis in asthmatics [128, 260-262]. Furthermore 
other pro-angiogenic factors (bFGF, angiogenin) could be attributed to vascular alterations 
occurring in the airways of asthma patients [128]. Besides the observation, that asthmatics 
have increased vessel number and size, several mediators of angiogenesis have been 
demonstrated to be elevated in asthma. It has been demonstrated that the submucosa of 
asthma patients contains more VEGF, bFGF and angiogenin compared to control subjects 
[128]. 
The aforementioned alterations in the bronchial vasculature contribute significantly to the 
pathology of asthma. They are correlated to asthma severity by influencing airflow 
limitation [252, 263, 264] and bronchial hyperresponsiveness [264-266]  
The correlations between the increased vascularization, airway wall remodeling, and 
disease pathology remain incompletely understood but recent studies provide evidence that 
vascular density and asthma severity are linked [128, 267-269]. 
The increased number of vessels adjacent to the BM and within the lamina propria might 
contribute to remodeling and asthma pathology in different ways. In response to 
vasodilating stimuli and in an inflammatory condition the increased number of vessels will 
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leak, causing tissue edema and thereby narrowing of the airways. The increased vascular 
permeability leads to plasma exudation into the surrounding tissue and might thereby 
submerge factors of inflammation and remodeling into the lung tissue. This effect might be 
amplified by proteoglycans, which have been deposited during BM thickening. These 
components of the ECM are able to sequestrate the plasma and thereby “store” mediators 
of inflammation as well as amplifying edematous effects. Last but not least an increased 
number of vessels results in increased blood supply to the lungs. This might supply the 
hyperplastic BSM layer with the required nutritions and oxygen. 
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Hypoxia  
General  
Hypoxia describes the diminished availability of oxygen in body tissues. It is observed in 
many physiological conditions such as embryonic development and differentiation or 
wound healing. Hypoxia may also occur as the consequences of several pathologies 
including tumor progression, interstitial lung diseases, ARDS, COPD, neoplasms, 
arteriosclerosis and asthma [270-272]. Hypoxia is always associated with the activation of 
proteins of the hypoxia inducible factor (HIF)-family. The activation of the HIF-pathway 
allows the cells to adapt to external factors (in this case the low oxygen concentration). The 
major component of hypoxia signaling is the transcription factor HIF, which is comprised 
of two subunits (HIF-α and HIF-β). The HIF-1β subunit is constitutively expressed and 
hetero-dimerizes with one out of its three potential binding partners HIF-1α, HIF-2α or 
HIF-3α. All HIF-α proteins have a very short half-life under normal oxygen conditions 
(normoxia) and are, by hydroxylation of two proline-residues in the oxygen-dependent 
degradation domain (ODDD), constantly targeted for proteasomal degradation [273]. 
Ubiquitinylation of hydroxylated HIFα is mediated by the von Hippel-Lindau protein 
(VHL) [274]. Under low oxygen concentrations hydroxylation is impaired and results in 
increased levels of HIF-α. HIF-α is then translocated to the nucleus, dimerizes with the 
HIF-β subunit and the active transcription factor binds to hypoxia response elements 
(HRE) in the promotor regions of downstream target genes [273]. Roughly 100 targets 
genes of the oxygen-sensing pathway are known and their corresponding proteins are 
implicated in tissue angiogenesis, erythropoiesis ventilation, glycolysis, and autophagy 
[275]. The activation of the HIF-dependent pathway is illustrated in Figure 6.  
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Figure 6: Schematic illustration of the HIF oxygen-sensing pathway. Under normal oxygenation HIF-α is 
hydroxylated, ubiqitinylated and finally proteasomal degraded. Low oxygen concentrations result in HIF 
stabilization and transcription of HIF target genes. Image from [276]. 
Potential role of hypoxia in asthma 
A role for hypoxia in the pathogenesis of asthma has been acknowledged only recently. In 
a rat model of asthma HIF is pivotal in promoting airway inflammation and elevated levels 
of this factor have been detected in endobronchial biopsies and BALF of asthmatics [271]. 
Furthermore, increased levels of the “oxygen-dependent” HIF subunits (HIF-1α and HIF-
1β) have been observed in lung tissues, epithelial cells and BALF of asthmatic patients. 
Here, the HIF expression and VEGF level were correlated [277].  
Although little is known about the impact or the role of hypoxia in the pathology of asthma 
or remodeling processes in asthma, hypoxia has been recognized in other (inflammatory) 
pulmonary diseases. Pulmonary disease associated with reduced ventilation, airway 
obstruction, intra-alveolar exudates and/or edematous septal thickening can lead to 
impaired gas exchange and thereby to reduced tissue and/or blood oxygenation. Cystic 
fibrosis (CF) is an autosomal recessive disorder cause by mutation in the Cystic fibrosis 
transmembrane conductance regulator (CFTR) gene coding for a chloride-channel. The 
disease is characterized by altered mucus composition, which results in impaired 
mucociliar clearance and the subsequent formation of mucus plaques. For CF it is 
suggested that, besides the increased energy consumption by bacteria (comorbidity), the 
mucus restricts the O2 diffusion and thereby causing hypoxia [278]. An example how 
reduced ventilation drive and airway obstruction might cause hypoxia is COPD. The 
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decreased oxygen transport leads to hypoxia in the alveoli of COPD patients and is 
accompanied by several alteration of the lung tissue including vascular alterations [272].  
Although several studies in animal models and from humans demonstrated an increased 
activation of hypoxia signaling cascade and its target genes the mechanisms of hypoxia-
induced signaling and its contribution to asthma pathology are far from understood. To 
understand hypoxia and angiogenesis in the remodeling process observed in the lung of 
asthma patients further investigation is needed. 
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Current asthma therapies 
First and foremost it should be noted that there is no cure for asthma. Fortunately most of 
the symptoms can be controlled quite effectively using several regimes of drugs. To date 
the standard therapy for asthmatic patients is inhaled or orally administered GC or a 
combination of GC and long acting 2 adrenergic receptor agonists (LABA).  
GC reduced the ongoing inflammation [79, 279, 280], improved the lung function [279], 
and lessened AHR [281, 282]. The mode of action of GC is via trans-activation of anti-
inflammatory as well as via trans-repression of pro-inflammatory mediators [14, 283]. 
LABA caused muscle relaxation and reduced bronchoconstriction by increasing cAMP 
level. LABA are used as part of the combination therapy in severe or difficult to treat 
asthmatics. In combination with LABA, the efficacy of GC can be enhanced, and the 
patient needs less GC to reach the same relief. Reducing the dose of GC by the use of 
combination therapy also reduces the systemic side effects such as osteoporosis, arterial 
hypertension, glaucoma, skin thinning, etc., which high doses of GC might have [284]. 
Although GC are quite effective in reducing the ongoing airway inflammation in 
asthmatics they do not affect BSMC proliferation [285]. The effect of GC on the airway 
epithelium is a controversial issue. Some studies showed a beneficial effect of GC on the 
epithelium [286] but others could not confirm these findings [287, 288]. Another 
controversial issue is the influence of GC on BM alterations. Some studies showed a 
reversion of BM thickening [289] and other did not find an effect [290]. Treatment of 
bronchial epithelial cells with GC and/or LABA in vitro caused a decrease in the release of 
pro-inflammatory and pro-angiogenic mediators [291, 292]. The beneficial effects of GC 
on vascular remodeling have been addressed in a murine model showing a significant 
inhibitory effect on angiogenesis [293, 294]. GC treatment has similar effects in asthmatic 
patients. Reduced vessels numbers, sprouting, and VEGF level have been observed in GC-
treated asthma patients [295, 296]. In summary the use of GC is only partially 
stopping/reversing the remodeling and some features of remodeling persist.  
The previously described heterogeneity of asthma is also reflected by another important 
fact: Asthma patients react differently to the existing asthma medications. In about 10% of 
the cases the available therapies do not have a satisfying effect [17].  
Several alternative strategies to treat severe or steroid resistant asthma exist or are in 
clinical trials. One example is the use of a humanized, neutralizing IgE-specific antibody in 
severe allergic asthma. This antibody binds free IgE and thereby reduces cell-bound IgE. It 
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has been shown that under this treatment the dose of GC could be reduced [297] and on 
long term the emergency visit rate was decreased as well as asthma exacerbation [298]. 
Another strategy, the administration of IL-4 receptor or IL-5 reducing antibodies failed in 
large clinical trials [299, 300] or did not have beneficial effects on the clinical outcome 
[81, 301, 302]. Currently there is a clinical trial going on testing a CCR4-specifc antibody 
in asthmatics. This antibody had beneficial effects in T cell leukemia by depletion of the T 
cells. As T cell recruitment play an important role in asthma pathogenesis it efficacy in the 
treatment of asthma will be tested in the future [303].  
Although Leukotriene-receptor-antagonists and 5-lipooxygenase inhibitors are no first-line 
treatment in asthma they are used with good results in difficult-to-treat patients [304-306]. 
Furthermore, anti-inflammatory drugs like muscarinic receptor antagonists, which have 
been used in the treatment of COPD for instance, have been shown in key clinical trials to 
have beneficial effects in asthma [307]. 
A new, invasive therapy option has been use in cases of uncontrolled asthma: thermoplasty. 
With this treatment locally restricted heating of the muscle tissue significantly reduces the 
mass of BSM with a laser. This technique has been used in several cases of severe asthma 
and the symptoms in those patients could be markedly reduced [308]. The efficacy of this 
therapy emphasizes the role of BSMC in the pathogenesis of asthma and a non-invasive 
reduction of BSM or slow down/reversal of remodeling processes might provide new 
therapeutic strategies. A long-term follow up of patients receiving thermoplasty revealed a 
stable lung function [308]. The beneficial effect of BSM mass reduction seems to be an 
attractive strategy to treat asthma patients. 
In conclusion, several treatment options exist, targeting almost all features that contribute 
to the pathology of asthma. Furthermore, several new treatments are in clinical trials either 
to use existing drugs or to study the effect of new compounds. Unfortunately there is no 
cure for asthma yet and treatment regimens do not meet the needs of every patient. 
Therefore, studies are need to prove efficacy of existing therapies, to provide 
guidelines/biomarkers to estimate treatment efficacy in a single patient and the search for a 
cure for the disease still goes on. 
 
 
In summary, this introduction points out the complexity of asthma with emphasis on 
different cellular aspects and mechanisms involved in its pathology. In summary, asthma 
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can be described as an environmental mediated disorder with a strong impact of genetic 
predeposition on the development and progression of the disease. The immune system and 
its mediating cells play an important role in the perpetuation of asthma symptoms and in 
acute exacerbations, but the impact of the resident cells of the lung tissue, as well as the 
components of the extracellular matrix is increasingly recognized. It is important to keep in 
mind that asthma is a complex, heterogeneous syndrome with several different clinical 
manifestations and varying severity. To date there is no cure for the disease although 
symptoms can be controlled in about 90% of the cases. This increasing complexity of the 
disease makes asthma a disease that is very hard to understand. The Lancet summarized 
this as follows: 
 
“Progress in understanding asthma is slow; treatment can be difficult and response 
unpredictable; and prevention and cure are still a pipedream.” (The Lancet, 2008) 
 
In conclusion, the cells and mechanisms described throughout the introduction may all 
contribute to the onset, persistence and outcome of asthma. Treatment of the disease, or the 
possibility of developing cures, should take the heterogeneity into account, or focus on 
holistic approaches that integrate these mechanisms. 
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OBJECTIVE OF THE THESIS 
Objective of the thesis 
Asthma is a chronic inflammatory respiratory disorder, which affects estimated 300 million 
people worldwide. Thus, asthma is a major health concern and currently there is no cure 
for asthma. Remodeling of the airway wall is a hallmark pathology of asthma manifesting 
as tissue structural changes. Amongst others, increased vascularity of the airway wall and 
an increased bulk of BSMC have been observed. The thickening of the basement 
membrane in asthmatic airway walls is one of the most prominent tissue structural changes 
linked to airway wall remodeling in asthma. Together with the increased BSMC mass and 
the inflammatory environment this may lead to a locally restricted hypoxic environment 
for the cells of the sub-epithelial cell layers in the airway wall of asthma patients. In my 
thesis the contribution of BSMC to asthma associated airway wall angiogenesis was 
assessed, comparing cells obtained from asthma patients to those of non-asthma subjects 
under different conditions. 
 
The specific objectives of my thesis were: 
I)  Comparison of the angiogenic potential of BSMC obtained from asthmatics 
compared to non-asthmatics and to identify factors that are produced by BSMC and 
support (induce) angiogenesis of the airway wall.  
II)  To investigate the effect of hypoxia on the release of angiogenic factors by BSMC 
and on the proliferation of BSMC. 
III) Effects of HDM allergens on the angiogenic properties of BSMC and their 
potential role in allergen-mediated angiogenesis.. 
 
In summary this thesis aims to contribute to the understanding of the pivotal role of BSMC 
in the pathogenesis of airway wall remodeling with a focus on the triangle of 
inflammation - resident tissue - forming lung cells (BSMC) - angiogenesis and the 
influence of low oxygen concentration and HDM allergens on the studied parameters. The 
findings may help to develop novel therapeutic strategies to inhibit the pathological effects 
of airway wall remodeling. 
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Abstract 
Background: Airway wall remodelling is a key pathology of asthma. It includes thickening 
of the airway wall, hypertrophy and hyperplasia of bronchial smooth muscle cells 
(BSMC), as well as an increased vascularity of the sub-epithelial cell layer. BSMC are 
known to be the effector cells of bronchoconstriction, but they are increasingly recognized 
as an important source of inflammatory mediators and angiogenic factors. 
Objective: To compare the angiogenic potential of BSMC of asthma and non-asthma 
patients and to identify asthma-specific angiogenic factors. 
Methods: Primary BSMC were isolated from human airway tissue of asthmatic and non-
asthmatic patients. Conditioned medium (CM) collected from BSMC isolates was tested 
for angiogenic capacity using the endothelial cell (EC)-spheroid in vitro angiogenesis 
assay. Angiogenic factors in CM were quantified using a human angiogenesis antibody 
array and enzyme linked immunosorbent assay.  
Results: Induction of sprout outgrowth from EC-spheroids by CM of BSMC obtained from 
asthma patients was increased compared with CM of control BSMC (twofold, p < 0.001). 
Levels of ENA-78, GRO-α and IL-8 were significantly elevated in CM of BSMC from 
asthma patients (p < 0.05 vs. non-asthmatic patients). SB 265610, a competitive antagonist 
of chemokine (CXC-motif) receptor 2 (CXCR2), attenuated the increased sprout outgrowth 
induced by CM of asthma patient-derived BSMC. 
Conclusions: BSMC isolated from asthma patients exhibit increased angiogenic potential. 
This effect is mediated through the CXCR2 ligands (ENA78, GRO-α and IL-8) produced 
by BSMC.  
Implications: CXCR2 ligands may play a decisive role in directing the neovascularization 
in the sub-epithelial cell layers of the lungs of asthma patients. Counteracting the CXCR2-
mediated neovascularization by pharmaceutical compounds may represent a novel strategy 
to reduce airway remodeling in asthma. 
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Abbreviations 
bFGF Basic fibroblast growth factor 
BSA Bovine serum albumin 
BSMC Bronchial smooth muscle cell 
CEBPα CCAAT/enhancer binding protein 
CM Conditioned medium 
CXCR2 Chemokine (C-X-C motif) receptor 2 
ECGM Endothelial cell growth medium 
ELISA Enzyme-linked immunosorbent assay 
ENA-78 Epithelial neutrophil-activating protein 78; epithelial cell-derived 
neutrophil attractant-78 
FCS Fetal calf serum 
FEV1 Forced expiratory volume in 1 second  
GRO-α Growth regulated oncogene-alpha 
HMEC-1 Human microvascular endothelial cell line 
IgG Immunoglobulin G 
IL Interleukin  
MCP-1 Monocyte chemotactic protein-1 
PBS Phosphate buffered saline 
TBST Tris buffered saline (with 0.1% Tween) 
TIMP Tissue inhibitor of metalloproteinases  
TRITC Tetramethyl Rhodamine Isothiocyanate 
VEGF Vascular endothelial growth factor 
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Introduction 
Asthma is a chronic inflammatory airway disease affecting over 300 million people 
worldwide with an expected increase of a further 100 million by 2025 [1, 2]. Although 
airway inflammation in asthma can be controlled, there is currently no cure for the disease 
and airway wall remodeling is unaffected by any asthma therapy. The etiology of asthma 
remains obscure and the pathology of asthma involves genetic predisposition and 
environmental factors. Increasing evidence suggests that inflammation is not the only 
cause of asthma and airway remodeling may be equally important [3]. Airway wall 
remodeling refers to persistent cellular and structural changes in the airway wall. In 
progressive disease, airway remodeling includes epithelial goblet cell hypertrophy, 
enhanced collagen deposition and airway wall hyperplasia [4-6]. 
It has been shown that bronchial smooth muscle cells (BSMC) isolated from asthma 
patients release more pro-inflammatory mediators than BSMC from control subjects [7-9]. 
These findings suggest that BSMC of asthma patients exhibit a hyper-reactive “primed” 
phenotype, which may be explained, at least in part, by an aberrant expression of the 
transcription regulator CCAAT/enhancer binding protein α (C/EBPα) [7, 10-12].  
Histological studies of airways in adults and children with asthma have variously provided 
evidence for increased microvessel density/vascularity and increased numbers of BSMC 
[13-17]. Increased airway vascularity has also been demonstrated in vivo in asthmatic 
patients by bronchovideoscopy [18]. Vascular endothelial growth factor (VEGF), a 
mediator of microvascular leakage, EC proliferation and vascular remodeling, was found 
in the airways of asthma patients [19, 20]. Furthermore, increased levels of angiogenin and 
monocyte chemotactic protein-1 (MCP-1) were also found in the airways and airway lining 
fluids (broncho-alveolar lavage fluid, sputum) of asthma patients [21]. More recently it 
was reported that BSMC were a source of angiogenic factors [22-24] and that BSMC 
derived from asthma patients could initiate and sustain angiogenesis in vitro through 
release of VEGF [24]. These data suggest that BSMC may direct neovascularization in 
sub-epithelial cell layers in the airways of asthma patients. In addition, CXCR2 ligands 
have been implicated in angiogenesis but mainly in the context of tumor 
neovascularization [25]. Here we hypothesize that CXCR2 ligands may also be involved in 
asthma associated airway wall angiogenesis. Better knowledge of the spectrum of potential 
angiogenic factors expressed by BSMC is crucial to therapy of angiogenesis-driven airway 
remodeling in asthma. Using in vitro angiogenesis assay, angiogenesis antibody array, 
  IN ASTHMA CRCR2 LIGANDS PROMOTE ANGIOGENESIS 
63 
enzyme linked immunosorbent assay (ELISA) and a competitive CXCR2-selective 
antagonist, this study demonstrates that BSMC derived from asthma patients exhibit 
increased angiogenic potential compared to controls that is mediated by CXCR2-ligands. 
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Methods 
Ethics statement 
Human airway tissue was obtained from explanted and resected lungs and post mortem 
organ donors with ethical approval from The University of Sydney and participating 
hospitals (Concord Repatriation General Hospital, Sydney South West Area Health Service 
and Royal Price Alfred Hospital) for sample collection. All volunteer, or their next of kin, 
provided written informed consent. The use of human primary BSMC was approved by 
local ethical committees (University Hospital, Basel, Switzerland, and University Hospital, 
Groningen, The Netherlands). Written informed consent was provided by each patient. 
Histochemistry of human airway tissue 
Human airway tissue was obtained from asthmatic patients and from healthy organ donors 
whose lungs were deemed unfit for use in a transplant procedure (for the samples used as 
non-diseased controls). Airway tissues were fixed in 4% phosphate-buffered formalin (pH 
7.2) and embedded in paraffin. Sections of 3 µm thickness were stained with Milligan’s 
trichrome and imaged using an Olympus BX60 microscope  equipped with a DP71 camera 
(Olympus, Hamburg, Germany).  
Isolation of primary BSMC from human airway tissue and preparation of conditioned 
medium 
Human airway tissues from 8 non-asthmatic (NA) and 9 asthmatic (A) patients were 
obtained either by endobronchial biopsy or therapeutic lung resection. BSMC were 
isolated from each individual tissue as described before [26, 27]. BSMC isolates were 
normally grown in BSMC growth medium (RPMI 1640 supplemented with 5% fetal calf 
serum (FCS), 1x antibiotics-antimycotics and 1x modified Eagle`s medium vitamin mix 
(Invitrogen, Lubio, Luzern, Switzerland)) under normoxic conditions (20% O2, 5% CO2, 
37 °C). BSMC were used at passages 3-10. 
For the preparation of conditioned medium (CM), BSMC were seeded at 10
5 
cells/well in 
6-well plates and grown in normal growth medium for 24 h. Cells were subjected to a 24 h 
period of serum-deprivation and then further cultured for 24 h and 72 h under resting 
(serum-deprived) or normal growth (5% FCS-containing) conditions. Proliferation 
experiments showed that cell numbers between asthmatics and non-asthmatics did not 
significantly differ in our experimental setting (fold increase in cell number after 72 h: 
asthmatics: 2.05 ± 0.15, non-asthmatics: 1.98 ± 0.21; p = 0.78). Culture supernatants/CM 
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were harvested, centrifuged to remove cells and stored at -80 °C until use. Every BSMC 
isolate was used for preparation of CM. All experiments (except endothelial cell tube 
formation assay) were performed with cell culture supernatant (24 h and 72 h, serum-
deprived) and CM (24 h and 72 h, 5% FCS). For any given BSMC isolate the experimental 
protocols for preparation of CM were performed on at least two independent occasions and 
in duplicate for each condition.  
Endothelial tube-formation assay 
Human microvascular endothelial cell (EC) line HMEC-1 [28] was normally maintained in 
EC growth medium (ECGM, Provitro, Bioconcept, Allschwil, Switzerland) supplemented 
with 10% FCS under normoxic conditions. Spheroids composed of 500 HMEC-1 cells 
were prepared using the hanging drop method [29]. The tube-forming (sprout outgrowth) 
assay was performed as previously described [30]. At least 10 spheroids per gel were 
embedded within fibrin gels in 48-well plates. Gels were overlaid with a 1:1 mixture of 
ECGM supplemented with 2% FCS and either normal BSMC growth medium (to 
determine spontaneous sprout outgrowth) or CM obtained from FCS-stimulated BSMC (to 
measure BSMC-dependent sprout outgrowth). CM (t = 72 h) of BSMC isolates from 3 
different asthmatic patients and 3 different controls were tested. To block the chemokine 
(CXC-motif) receptor 2 (CXCR2) the competitive antagonist SB 265610 [31, 32] was 
included within the fibrin gel and medium overlay. After incubation for 24 h, spheroids 
were fixed in-gel, stained with TRITC-conjugated phalloidin and sprout outgrowth from 
each spheroid was quantitated by morphometric analysis of the length of outgrowing 
tubules [326]. For each well the mean of the 10 longest tubules per spheroid was 
quantitated by morphometric analysis of the length of outgrowing tubules using AnalySIS 
software (Soft Imaging System GmbH, Munich, Germany). This value was used to 
calculate the mean ± S.E.M.  
Viability and proliferation assays 
HMEC-1 were seeded at 7.5x10
4 
cells/well in 48-well plates, grown for 24 h, serum-
deprived for 24 h and then further cultured in ECGM/10% FCS without or with inclusion 
of SB 265610. Viability was examined after 24 h by Trypan blue staining and manual cell 
counting using a Neubauer chamber. Proliferation was measured after 48 h by enzymatic 
disaggregation and cell enumeration using a Beckman Coulter particle counter Z1 (Nyon, 
Switzerland). 
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Immunocytochemistry  
HMEC-1 were grown in 24-well-plates to 70% confluency and fixed in 4% PFA (20 min). 
Cells were permeabilized by incubation (5 min) in PBS containing 0.5% Triton X-100 and 
1% bovine serum albumin (BSA) and unspecific binding was blocked by incubation (1 h) 
in PBS containing 5% BSA. Cells were incubated for 2 h with either mouse anti-CXCR2 
IgG (Abcam, Lucerna-Chem, Luzern, Switzerland) or non-immune mouse IgG (DAKO, 
Baar, Switzerland), washed (PBS containing 0.05% Triton X-100) and then incubated with 
FITC-conjugated secondary anti-mouse IgG (Southern Biotech, Bioconcept, Allschwil, 
Switzerland). Nuclei were counterstained using Hoechst 33342 (200 ng/ml in PBS, 5 min). 
Images were taken with an Olympus IX50 inverted microscope (Olympus, Hamburg, 
Germany) equipped with a Color View II camera; exposure time was constant for both 
conditions. 
Angiogenesis Antibody Array 
To identify angiogenic factors in the CM of FCS-stimulated BSMC the Human 
Angiogenesis Antibody Array G Series 1 (Raybiotech, Lucerna-Chem, Luzern, 
Switzerland) specific for 20 angiogenesis-relevant proteins (antibody array map provided 
in Figure 3) was used. The array test was performed on four separate occasions; on any 
given occasion CM and cell culture supernatant of BSMC-derived from asthmatic and non-
asthmatic patients were tested in parallel. BSMC isolates from 4 different asthmatic and 4 
different non-asthmatic patients were used. 100 µl aliquots of undiluted CM/cell culture 
supernatant were applied to each sub-array and the expression levels of angiogenesis-
relevant factors were determined according to the manufacturer’s instructions. Cy3-
fluoresence was measured using a NimbleGen MS 200 microarray Scanner (Roche, Basel, 
Switzerland) and signal intensities were analyzed with AIDA software (Raytest, 
Straubenhardt, Germany). Control experiments with BSMC growth or starving medium 
respectively were performed and revealed no unspecific signals due to the culture medium 
(no FCS or 5% FCS). Intensity ratios between asthmatic and control samples were 
calculated (normalized to the internal reference positive control); a ratio of ≥ 1.3 was 
considered significantly different as indicated by the manufacturer. 
Cytokine-ELISA 
ELISA kits for epithelial neutrophil-activating protein 78 (ENA-78), growth regulated 
oncogene α (GRO-α), and VEGF-A were from R&D (Abingdon. UK). ELISA kit for IL-8 
was from Orgenium (Anibiotech, Vantaa, Finland). ELISAs were performed according to 
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the respective manufacturer´s instructions. For these experiments, we used CM of BSMC 
isolates from 6 different asthmatic patients and 6 different controls.  
RT-PCR 
HMEC-1 cells were plated in a 25 cm
2
 cell culture flask and grown to confluency. Cells 
were washed 2x with DPBS and total RNA was isolated using RNeasy Mini kit (Qiagen, 
Hombrechtikon, Switzerland) according to the manufacturer`s instructions. RNA 
concentration was determined by spectroscopy (NanoDrop, Witec, Luzern, Switzerland). 
First strand DNA was synthesized with m-MLV Reverse Transcriptase (Promega, 
Dübendorf, Switzerland) from 2.5 µg of total RNA. The obtained cDNA was subjected to 
amplification with HotStarTaq Plus DNA polymerase (Qiagen, Hombrechtikon, 
Switzerland) using the following CXCR2-specific primers: forward 5`-CAG TTA CAG 
CTC TAC CCT GCC–3, reverse 5`-CCA GGA GCA AGG ACA GAC CCC–3 generating a 
451 bp spanning fragment. PCR conditions were: 5 min 95°C; 32x: 30 sec 98°C, 30 sec 
58°C, 1 min 72°C; 10 min 71°C. PCR products were size-fractioned on a 1% agarose gel, 
stained with ethidium bromide and visualized under UV light. 
Statistics 
Data was analyzed using Microsoft Excel and Graph Pad Prism software. Student`s t-test 
(Spheroid analysis) and Mann-Whitney test (ELISA) have been performed. A p-value of < 
0.05 was considered significant.  
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Results 
Increased vascularization in human tissue sections from the lung of asthma patients 
Patients with mild to moderate asthma (n = 9, 4 females/5 males, age 23-60 years) had 
reversible airway obstruction documented in the past, with median FEV1 of 84.6% of the 
predicted value (ranging from 68.5% to 124.9%). Milligan’s trichrome staining of human 
airway tissue cross-sections demonstrated marked differences between non-asthmatic 
(Figure 1A) and asthmatic (Figure 1B) patients; the airway walls of asthmatic patients 
exhibited hyperplastic epithelium, increased thickness of the basement membrane, 
increased bulk of smooth muscle bundles, as well as increased microvessel density within 
sub-epithelial cell layers. 
 
Figure 1: Milligan’s trichrome stained sections of airway tissue from non-asthma (A) and asthma (B) 
patients. Images are representative of tissues obtained from 3 non-asthmatic and 3 asthmatic patients. Nuclei 
and muscle: magenta, collagen: green, RBC: orange. Note epithelial hyperplasia, thickening of muscle 
bundles and basement membrane, and increased microvessel density in asthmatic airways. E = epithelium, 
MB = muscle bundles, BM = basement membrane, MV = microvessels. 
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Increased angiogenic potential of BSMC obtained from asthmatics 
Angiogenic potential of culture supernatants (CM) collected from normally growing 
BSMC of asthmatics and non-asthmatics was examined using the EC-spheroid in vitro 
angiogenesis assay. Spheroids were also cultured in unconditioned medium (i.e. with 
medium that had not been included with BSMC) to control for “spontaneous” sprout 
outgrowth. Figure 2 presents representative images of spheroids (Figure 2A) and the 
quantitation of sprout outgrowth into the 3D fibrin-gel matrix as mean tubule 
length/spheroid (Figure 2B) after a 24 h culture period.  
 
Incubation of EC-spheroids with CM of BSMC from asthmatic patients resulted in a 
twofold increase in sprout outgrowth as compared with CM of BSMC from non-asthmatic 
patients (p < 0.001). In the latter, sprout outgrowth was not significantly different from 
“spontaneous” outgrowth (p = 0.43). Thus the angiogenic potential of BSMC isolates 
derived from asthmatic patients is likely due to their secretion of pro-angiogenic factors 
into culture supernatants. 
Figure 2: Angiogenesis assay in vitro. 
A, Images illustrating sprout 
outgrowth from EC-spheroids 
incubated with unconditioned control 
medium or CM from BSMC. B, 
Lengths of sprouts outgrowing from 
every spheroid were measured and the 
mean of the longest 10 sprouts was 
calculated. Experiments were 
performed on 3 separate occasions 
using control medium and CM derived 
from 3 different non-asthmatic (NA) 
and asthmatic (A) patients. Values are 
given as mean ± SD. *** p < 0.001. 
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Identification of differentially expressed angiogenic factors in BMSC of asthmatics vs. 
non-asthmatics 
We used a Raybiotech angiogenesis antibody array to identify and compare expression 
levels of soluble BSMC-derived angiogenic and angiostatic factors in the CM of normally 
growing BSMC derived from non-asthmatic and asthmatic patients (Figure 3A-3D and 
S1). The array identified six factors that were present at higher levels in the CM of BSMC 
obtained from asthmatics patients, namely angiogenin, ENA-78, GRO-α, IL-6, IL-8 and 
MCP-1 (Figure 3D). ENA-78, GRO-α and IL-8 share the same receptor (CXCR2), and 
have therefore been the focus of all further studies.  
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Figure 3: Human angiogenesis antibody array. Examples of the angiogenesis antibody array (exp. 3) 
comparing CM from BSMC of non-asthmatic (A) and asthmatic (B) patients. C, Antibody array map. 
Standard abbreviations for the detected proteins are used, Pos: positive control, Neg: negative control, IC1-
IC3: internal controls 1-3. D, Quantitative analysis from each of the 4 independent experiments performed. 
Intensity ratios (A:NA) in a paired analysis are shown. Upregulation in any single experiment is indicated by 
a cross. nq = not quantifiable (out of range). 
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Figure S1: Human angiogenesis antibody array. Examples of the angiogenesis antibody array (exp. 4) 
comparing CM from BSMC of non-asthmatic (A) and asthmatic (B) patients of a longer exposure time to 
demonstrate differential expression levels in proteins with a low signal (e.g. ENA-78). C, Antibody array 
map. Standard abbreviations for the detected proteins are used, Pos: positive control, Neg: negative control, 
IC1-IC3: internal controls 1-3. 
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Increased CXCR2-ligands secretion by BSMC of asthmatics 
To validate the array findings we elected to measure levels of GRO-α , IL-8 and ENA-78  
in CM by ELISA; these all belong to the family of CXC-chemokines and signal via the 
shared receptor CXCR2 [329]. After 24 h resting culture conditions (without FCS) BSMC 
from asthma patients and control subjects secreted comparable amounts of GRO-α, IL-8, 
and ENA-78 (Table 1). After 72 h resting conditions levels of GRO-α, IL-8, and ENA-78 
were significantly greater in CM of BSMC from asthmatic patients than from non-
asthmatic patients (p < 0.05) (Table 1). Figure 4 shows levels of the measured secreted 
chemokines in CM from each of the tested BSMC after 24 h or 72 h periods of culture 
under normal growth conditions (presence of 5% FCS). Levels of GRO-α (Figure 4A), IL-
8 (Figure 4B) and ENA-78 (Figure 4C) were significantly greater in CM of BSMC from 
asthmatic patients than from non-asthmatic patients (p < 0.05; all values summarized in 
Table 1).  
 
Table 1: Summary of the levels (ng/ml) of CXCR2 ligands GRO-α, IL-8 and ENA-78. Concentration of 
the cytokines were measured in CM of BSMC from non-asthmatic (NA) and asthmatic (A) patients (n = 6 per 
group) after 24 h and 72 h culture under resting (serum-free) and normal growth (presence of 5% FCS) 
conditions. p-values were calculated using Mann Whitney U test. 
 FCS 
(5%) 
24 hours 72 hours 
 
NA A p-value NA A p-value 
GRO-α 
- 0.49 ± 0.30 0.60 ± 0.26 0.370 2.54 ± 1.66 3.50 ± 0.87 0.002 
+ 2.24 ± 1.00 5.68 ± 2.00 >0.0001 4.40 ± 2.01 10.10 ± 3.23 0.022 
IL-8 
- 1.27 ± 0.47 1.69 ± 1.02 0.750 1.51 ± 0.51 5.82 ± 3.53 0.026 
+ 3.80 ± 1.22 9.67 ± 2.05 0.002 5.23 ± 1.34 12.42 ± 2.08 0.002 
ENA-78 
- 0.11 ± 0.04 0.07 ± 0.03 0.625 0.23 ± 0.16 0.32 ± 0.12 0.016 
+ 0.42 ± 0.23 0.89 ± 0.33 0.021 1.00 ± 0.60 1.62 ± 0.72 0.023 
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Figure 4: Chemokine release from BSMC derived from asthmatics and non-asthmatics. Concentrations 
of GRO-α (A), IL-8 (B) and ENA-78 (C) in CM were collected from BSMC of non-asthmatic (NA) and 
asthmatic (A) patients after 24 h and 72 h were determined by ELISA.* p < 0.05 (n = 6). 
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Figure S2 illustrates the high variance between cell isolates of different patients with 
respect to the concentrations and predominance of specific CXCR2 angiogenic factors. 
 
Previously, Simcock et al. demonstrated that VEGF was the predominant factor released 
by TGF-β1- and/or IL-13-stimulated BSMC and that BSMC of asthma patients increased 
endothelial cell tube formation through VEGF [260]. Therefore, we screened our samples 
for VEGF protein by ELISA. BSMC obtained from asthmatics secreted significantly more 
VEGF compared to non-asthmatics (301 ± 48 pg/ml versus 179 ± 34 pg/ml, respectively; 
mean ± S.E.M.; p < 0.05, Figure S3).  
 
Figure S2: Chemokine release from BSMC 
derived from asthmatics and non-
asthmatics. This figure illustrates the 
concentrations and proportions of the released 
mediators for any single subject. 
Concentrations of GRO-α (A), IL-8 (B) and 
ENA-78 (C) in CM collected from BSMC of 
6 non-asthmatic (NA1-NA6) and 6 asthmatic 
(A1-A6) patients after 72 h determined by 
ELISA. Median was calculated from all 
values (A and NA) * p < 0.05 (n = 6). 
 
Figure S3: VEGF release by BSMC of 
asthmatic (A) and non-asthmatic (NA) 
subjects. BSMC were grown for 72 h in 
the presence of 5% FCS and VEGF was 
measured by ELISA. * p < 0.05, n=13 (A) 
and n=10 (NA).  
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Increased angiogenic potential of BSMC obtained from asthmatics is reversed by 
blocking CXCR2 with the competitive agonist SB 265610 
Since GRO-α, ENA-78 and IL-8 exert their biological effects through CXCR2, their 
proangiogenic actions should be attenuated by the competitive CXCR2-selective 
antagonist SB 265610. CXCR2 expression by HMEC-1 cells was demonstrated by RT- 
PCR analysis of total RNA from HMEC-1 cells (Figure 5A); amplification of cDNA with 
CXCR2 specific primer demonstrates CXCR2 expression from HMEC-1 cells. 
Immunofluorescence staining protocols confirmed the presence of CXCR2 on HMEC-1 
cells (Figure 5B). SB 265610 did not affect proliferation (Figure 5C) or viability (Figure 
5D) of HMEC-1 monolayers (in ECGM/10% FCS). Furthermore, SB 265610 added alone 
did not affect basal sprout outgrowth in the EC-spheroid assay (data not shown). In 
contrast sprout outgrowth induced by CM of BSMC from asthma patients was markedly 
attenuated (p < 0.001) by SB 265610, even at the lowest dose (Figure 5E). 
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Figure 5: Involvement of CXCR2 in BSMC-induced neovascularization. A, RT-PCR of CXCR2 in 
HMEC-1. B, Immunofluorescence detection of CXCR2 on HMEC-1. C, D, HMEC-1 monolayers under 
normal EC growth conditions were cultured without or with SB 265610 for 48h (C) or 24h (D) (mean ± SD, 
n=3) and evaluated for proliferation (C) and viability (D). E, Effect of SB 265610 on sprout outgrowth 
induced by CM of BSMC from asthmatics. Values are mean ± S.E.M. after normalization to the control 
condition. *** p < 0.001 (n ≥ 3). 
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Discussion 
This study has demonstrated that BSMC from asthma patients have an increased 
angiogenic potential compared to BSMC from non-asthma control subjects. Angiogenesis 
antibody arrays revealed that CM of BSMC from asthma patients contained significantly 
higher levels of angiogenin, ENA-78, GRO-α, IL-6, IL-8 and MCP-1. Increased 
production of the CXCR2 ligands ENA-78, GRO-α and IL-8 was confirmed by ELISA and 
functionality of CXCR2 ligands in mediating pro-angiogenic effects of BSMC from 
asthma patients was demonstrated by reduction of EC sprout outgrowth in the presence of 
the specific CXCR2 antagonist SB 265610.  
Neovascularization is increasingly recognized as an important feature of airway wall 
remodeling in asthma and it has become a topic of major interest. The Milligan’s 
Trichrome staining of airway tissue sections presented in this study demonstrated that 
neovascularization occurs in close proximity to BSMC. Therefore, BSMC may play a more 
important role in the process of angiogenesis than previously considered. Several studies 
have examined mechanisms underlying angiogenesis in airway wall remodeling, and 
demonstrated roles for basic fibroblast growth factor (bFGF), angiogenin, endostatin and 
VEGF [20, 21, 24 34-36]. The study by Simcock et al. is of particular interest because they 
also used human airway smooth muscle cells isolated from non-asthmatic and asthmatic 
patients and a similar angiogenesis antibody array to that used in this study [24]. They 
found that BSMC from asthmatic patients produced higher levels of angiogenin, 
angiopoietin, VEGF, EGF, IGF-1, IFNγ, TIMP-1 and TIMP-2 in response to stimulation 
with either IL-13 or TGF-β [20, 24]. We found that in the presence of 5% FCS human 
BSMC of asthma patients released a different complement of angiogenic regulators 
including angiogenin, IL-6, MCP-1 and importantly three CXCR2 ligands, namely ENA-
78, GRO-α and IL-8. ELISA assay revealed that BSMC of asthma patients also released 
significantly more VEGF than BSMC of controls. However, VEGF levels were low 
compared to other studies (pg/ml range rather than ng/ml) [20, 24] and below 
concentrations generally used to induce in vitro angiogenesis [24, 30, 37]. The very low 
concentration of VEGF in CM of FCS-cultured BSMC may explain why we could not 
detect VEGF with the antibody array we used. The discrepancy between the two studies 
regarding VEGF expression might be due to the use of different antibody array techniques 
(membrane [24] versus glass platform based array). It is also likely that production of any 
specific set of angiogenic regulators by BSMC is context dependent and is defined by the 
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microenvironmental setting, meaning that stimulation with IL-13 or TGF-β20 may induce 
a distinctly different set of angiogenic factors relative to stimulation with FCS. 
Additionally, intra-and inter-study variations with respect to specific composition and 
quantity of angiogenic factors produced might also reflect the heterogeneous character of 
asthma [38]. Nonetheless, both studies underscore the importance of enhanced release of 
angiogenic factors by BSMC from asthmatic patients.  
CXCR2 ligands are known mediators of angiogenesis mainly in the context of tumor 
angiogenesis [25] and in other diseases like idiopathic pulmonary fibrosis [39, 40] where 
angiogenesis plays a role. To the best of our knowledge the increased release of this set of 
CXCR2 ligands (ENA-78, GRO-α and IL-8) from BSMC from asthmatic patients 
stimulated with FCS has not been reported before; neither has this release been linked to 
the induction of angiogenesis in the context of asthma airway remodeling. ENA-78, GRO-
α, and IL-8 all mediate their angiogenic effect through CXCR2, although IL-8 has also 
been shown to bind the CXCR1-receptor [41]. Our findings point toward a previously 
unrecognized role for CXCR2 and its ligands in directing endothelial cell activation and 
neovascularization in asthma specifically, because slightly lower levels of these ligands 
present in CM of non-asthmatic controls did not significantly affect sprout outgrowth from 
endothelial cell spheroids. This may indicate that only BSMC obtained from asthmatics 
produce sufficient factors to reach the threshold required to induce sprouting.   
CXCR2 is expressed in several different tissues and cell types including cells of the 
immune system, epithelial cells, EC and cells of the nervous system [42]. Our study 
showed that CXCR2 is expressed on HMEC-1 and functionally relevant since CXCR2 
antagonist SB 265610 diminished sprout outgrowth induced by CM of BSMC from 
asthmatic patients. SB 265610 is considered a competitive antagonist and an allosteric 
inverse agonist of CXCR2 and has been shown to be a highly specific inhibitor for this 
receptor [31]. This observation may be the first step towards a new specific treatment of 
remodeling in the airway wall of asthma patients.  
In asthma patients, increased BSMC mass [14, 17, 27] and increased number of 
mitochondria in BSMC [43] have been observed, which suggests increased energy 
consumption and an according prompt for induction of angiogenesis to supply the cells 
with nutrition and oxygen. Therefore, reducing neovascularization in the sub-epithelial cell 
layers of the airway wall of asthma patients might help to reduce airway wall remodeling. 
Clinical studies have shown that symptoms of severe asthma could be markedly reduced 
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by the use of thermoplasty of specifically the bronchial smooth muscle cell layer [44]. The 
heating of the airways led to a decrease in the amount/mass of BSM [45] and reduced the 
frequency of asthmatic exacerbations [46], thus supporting increased BSM mass as being a 
key feature of airway remodeling in asthma. Blocking CXCR2 and thereby inhibiting 
BSMC-dependent angiogenesis and associated airway wall remodeling may therefore have 
a similar beneficial effect.  
Identification of factors that might ubiquitously regulate and/or control pathological 
features in the asthmatic lung remains a challenge. Our study presents CXCR2-ligands 
(GRO-α, ENA-78, IL-8) as candidate factors contributing toward angiogenesis and airway 
wall remodeling in asthma. Studies with CXCR2-blockers and ligand-neutralizing agents 
in the context of different diseases (such as rheumatoid arthritis, COPD) are ongoing [42, 
47]. Our findings open a door to exploiting CXCR2-targeted treatments for bronchial 
asthma as well. 
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Abstract 
Background: For oxygen supply, airway wall cells depend on diffusion though the 
basement membrane, as well as on delivery by microvessels. In the asthmatic lung, local 
hypoxic conditions may occur due to increased thickness and altered composition of the 
basement membrane, as well as due to edema of the inflamed airway wall. 
Objective: In our study we investigated the effect of hypoxia on proliferation and pro-
inflammatory and pro-angiogenic parameter production by human bronchial smooth 
muscle cells (BSMC). Furthermore, conditioned media of hypoxia-exposed BSMC was 
tested for its ability to induce sprout outgrowth from endothelial cells spheroids. 
Methods: BSMC were cultured in RPMI1640 (5% FCS) under normoxic (21% O2) and 
hypoxic (1% and 5% O2) conditions. Proliferation was determined by cell count and 
Western blot analysis for cyclin E and Proliferating Cell Nuclear Antigen (PCNA). 
Secretion of IL-6, IL-8, ENA-78 and VEGF was analyzed by ELISA. BSMC conditioned 
medium was tested for its angiogenic capacity by endothelial cell (EC)-spheroid in vitro 
angiogenesis assay. 
Results: Proliferation of BSMC obtained from asthmatic and non-asthmatic patients was 
significantly reduced under severe hypoxia (1% O2), whereas moderate hypoxia (5% O2) 
only reduced proliferation of asthmatic BSMC. Hypoxia induced HIF-1α expression in  
asthmatic and non-asthmatic BSMC, which coincided with significantly increased release 
of IL-6, IL-8 and VEGF, but not ENA-78. Finally, sprout outgrowth from EC spheroids 
was increased when exposed to hypoxia conditioned BSMC medium. 
Conclusion: Hypoxia had dualistic effects on proliferative and inflammatory responses of 
both asthmatic and non-asthmatic BSMC. First, hypoxia reduced BSMC proliferation. 
Second, hypoxia induced a pro-inflammatory, pro-angiogenic response. BSMC and 
endothelial cells may thus be promising new targets to counteract and/or alleviate airway 
wall remodeling.  
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Introduction 
Persistent airway wall remodeling is an important pathology of asthma, which is 
characterized by basement membrane thickening, increased bronchial smooth muscle 
(BSM) mass and neovascularization. Together with enhanced extracellular matrix 
deposition these pathologies result in thickening of the basement membrane and the 
underlying tissue layers. It is of interest that BSMC from asthmatic patients have a distinct 
“phenotype” compare to cells from non-asthma subjects [1]. This disease specific 
phenomenon is associated with diminished expression of the CCAAT/enhancer binding 
protein (C/EBP)-α in BSMC of asthma patients [2-5]. Lower C/EBP-alpha levels may 
explain several parameters associated with the hyper-reactive (“primed”) phenotype of the 
asthmatic BSMC, including an increased release of pro-inflammatory factors and 
mediators [6, 7]. Smooth muscle changes in allergic asthma include myofibroblast 
differentiation, BSMC hyperplasia and hypertrophy and vascular smooth muscle 
thickening [8].  
For oxygen supply, BSMC depend on direct diffusion though the basement membrane, as 
well as on oxygen delivered by microvessels present in the airway wall. In the asthmatic 
airway, local hypoxic conditions may occur due to increased thickness and altered 
composition of the basement membrane, as well as of edema, which may affect the rate of 
oxygen diffusion [9]. In healthy lungs, the thickness of the basement membrane measures 
5-7 µm, while in asthmatics the size was found up to 5 times increased [10]. Even in young 
asthmatic children the basement membrane was significantly thicker compared to non-
asthmatic controls [11]. The increased thickness of the basement membrane may readily 
induce a locally restricted hypoxic environment, which affects the properties and behavior 
of BSMC. In addition, increased oxygen consumption by inflammatory cells and growing 
BSMC may further add to locally restricted hypoxic conditions in the lung [9].  
It had only recently been suggested that hypoxia may play a role in the pathogenesis of 
asthma. For instance, hypoxia aggravated airway inflammation, remodeling, and furthered 
the development of asthma in a murine model of asthma [12]. The activation of proteins of 
the hypoxia inducible factor (HIF)-family is a major regulator of the cellular response to 
hypoxia [13] and increased level of HIF-α, have been detected in endobronchial biopsies 
and in the broncho-alveolar lavage fluid (BALF) of asthma patients [12]. Similarly, 
increased levels of the HIF subunits (HIF-1α and HIF-1β) have been observed in lung 
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tissue, epithelial cells and BALF of asthma patients and have been correlated with the level 
of VEGF [14].  
In order to overcome hypoxia, resident cells of the airway wall, including BSMC and 
fibroblasts, may induce the production of angiogenic factors leading to the formation of 
new microvessels in the airway wall. Indeed, VEGF one of the most potent angiogenic 
factors, is produced by smooth muscle cells [15-17] and is able, to stimulate the 
proliferation of vascular smooth muscle cells [18, 19]. These findings indicate that BSMC 
are able to induce angiogenesis and may direct the observed neovascularization of the 
airway wall.  
In our present study we examined the effects of hypoxia on inflammatory and proliferative 
responses of BSMC obtained from the lungs of both healthy and asthmatic subjects. Our 
data demonstrate that hypoxia diminished the proliferation-rate of BSMC, whereas it 
concomitantly induced HIF-1α and the subsequent the release of VEGF, IL-6 and IL-8. 
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Methods 
Patients 
Patients with mild to moderate asthma (n = 7, 3 females/4 males, age 23-64 years) had 
reversible airway obstruction documented in the past, with a median FEV1 of 70,5% of the 
predicted value (ranging from 45,3% to 84,6%). 
Cryosectioning, staining and light microscopy of endobronchial biopsies  
Superficial endobronchial biopsy specimens of the airway mucosa were immediately snap 
frozen in optimal cutting temperature (OCT) medium (Tissue-Tek, Sakura Finetechnical, 
Tokyo, Japan) on a cork disc by immersion in isopentane (2-methylbutane, HPLC grade, 
Sigma-Aldrich) suspended in liquid nitrogen and kept at -80ºC. Frozen biopsies were 
sectioned on a cryostat (Shandon Cryotome 620E) at -18ºC into sections of 7 µm and 
stored at -80ºC. The frozen sections were air dried at room temperature, fixed in 50% 
acetone/50% methanol (90 s) and stained with Harris’s haematoxylin and alcoholic eosin 
(Fronine Laboratory Supplies, Taren Point, Australia). Light microscopic photographic 
images were taken at 60x (Olympus AX70 microscope, DP50 camera). 
Isolation of primary bronchial smooth muscle cells  
BSMC were obtained from endobronchial biopsies by flexible bronchoscopy or 
therapeutically resected lung tissue (Department of Internal Medicine, Pneumology, 
University Hospital Basel, Basel, Switzerland) with the approval of the local ethical 
committees and written informed consent of all patients. Isolation of BSMC was 
performed as described earlier [1, 20] with some modifications. BSMC bundles were 
dissected from the surrounding tissue using a binocular microscope. Muscle bundles were 
then placed in a 25 cm
2
-flask in 1 ml Dulbecco`s modified Eagle`s medium (DMEM) 
containing GlutaMax-I 4.5 g/l glucose (Gibco
®
, Bioconcept, Allschwil, Switzerland), 5% 
FCS, 1x antibiotics-antimycotics, and 1x modified Eagle`s medium vitamin mix 
(Invitrogen, Lubio, Luzern, Switzerland). BSMC were characterized by 
immunofluorescence as described earlier [21]. 
BSMC culture  
BSMC were grown in BSMC-growth medium (GM): RPMI 1640 supplemented with 5% 
fetal calf serum (FCS), 8 mM L-glutamine, 20 mM hydroxyethyl piperazine ethane 
sulfonic acid, 1x antiobiotics-antimycotics and 1x modified Eagle’s medium vitamin mix 
(Invitrogen, Lubio, Luzern, Switzerland) under normoxic conditions (21% O2, 5% CO2, 37 
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°C) until they reached confluency and then subcultured. To study hypoxia, cells were 
cultured at oxygen concentrations of 1% and 5% (5% CO2, 37 °C). Conditioned cell 
culture medium was harvested after 72 h and kept at -20 °C until analysis. All experiments 
were performed at least in duplicates. Conditioned media (CM) used in endothelial cell 
sprout outgrowth assays was obtained from BSMC grown under hypoxic (1% O2, 5% CO2, 
37 °C, 72 hours) and normoxic conditions (21% O2, 5% CO2, 37 °C, 72 hours).  
Proliferation experiments  
To determine the effect of hypoxia on proliferation BSMC were seeded at 5x10
5
 cells/well 
in 12 well plates, allowed to adhere for 24 h in BSMC-GM, serum deprived for 24 h prior 
to stimulation and then cultured for 72 h in the presence or absence of 5% FCS under three 
different oxygen concentrations (21%, 5% or 1% O2). Cell counts were performed in 
duplicates before stimulation and after 72 h using a particle counter (Beckman Coulter 
particle counter Z1, Nyon, Switzerland).  
SDS-PAGE and Western blot  
Total protein lysates were size-fractioned on gradient (4-20%) Tris-HEPES gels (Pierce, 
Thermo-Scientific, Lausanne, Switzerland) and transferred to nitrocellulose membranes as 
described earlier [4]. Membranes were blocked for 30 min with 3% BSA in Tris buffered 
saline with 0.1% Tween 20 (TBST) for detection of PCNA, cyclin E, α-tubulin, GAPDH 
(Santa Cruz Biotech, Lucerna-Chem, Luzern, Switzerland) or for 1 h in 5% BSA in TBST  
for detection of HIF-1α (Cell Signaling Technologies, Bioconcept, Allschwil, Switzerland). 
Primary antibodies were applied for 2 h at RT in TBST/1%BSA (PCNA, cyclin E, α-
tubulin, GAPDH) or overnight at 4°C in TBST/5%BSA (HIF-1α). After 3x washing with 
TBST the HRP-conjugated species-specific secondary antibodies were applied for 30 min 
(PCNA, cyclin E, α-tubulin, GAPDH) in TBST or for 2 h in 3% milk powder in TBST 
(HIF-1α). After 3 washes the membrane were incubated with SuperSignal Western Pico 
Chemiluminescent Substrate (Pierce, Thermo-Scientific, Lausanne, Switzerland) for 5 min. 
Signal were detected on Fujifilm Super RX X-ray films (Lucerna-Chem, Luzern, 
Switzerland) and developed in a Curix60 film-processor (Agfa, Dübendorf, Switzerland). 
Cytokine-ELISA  
Enzyme linked immunosorbent assay (ELISA) kits for ENA-78, IL-6, IL-8 and VEGF-A 
were purchased from R&D (Abingdon. UK) and performed according to the 
manufacturer´s instructions. Cytokine levels were determined in 100 µl of CM obtained 
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from BSMC and were measured undiluted (VEGF A), 1:5 diluted (ENA-78, IL-6) or 1:50 
diluted (IL-8).  
Endothelial tube-formation assay  
Human microvascular endothelial cells (EC) HMEC-1 [22] were normally maintained in 
EC growth medium (ECGM, Provitro, Bioconcept, Allschwil, Switzerland) supplemented 
with 10% FCS under normoxic conditions. Spheroids composed of 500 HMEC-1 cells 
were prepared using the hanging drop method [23]. The tube-forming (sprout outgrowth) 
assay was performed as previously described [24]. At least 10 spheroids per gel were 
embedded within fibrin gels in 48-well plates. Gels were overlaid with a 1:1 mixture of 
ECGM supplemented with 2% FCS and either BSMC medium (to determine spontaneous 
sprout outgrowth) or CM obtained from BSMC grown under hypoxic (1% O2) and 
normoxic (21% O2) conditions. In experiments studying the effects of the CXCR2 
antagonist SB 265610 (Sigma-Aldrich, Buchs, Switzerland) the inhibitor was added to the 
gel 1 h prior to stimulation with CM. VEGF neutralizing antibody (R&D, Abigdon, UK) 
was added to CM for 1 h (37°C) prior to its addition to the gels containing the spheroids. 
After incubation for 24 h, spheroids were fixed in-gel, stained with TRITC-conjugated 
phalloidin (Sigma-Aldrich, Buchs, Switzerland) and sprout outgrowth from each spheroid 
was quantitated by morphometric analysis of the length of outgrowing tubules [24]. The 
length of the 10 longest tubules per spheroid of 7 randomly chosen spheroids/well was 
quantitated by morphometric analysis using AnalySIS software (Soft Imaging System 
GmbH, Munich, Germany) and the mean ± S.E.M. was calculated.  
Statistics  
Cytokine and proliferation data are presented as mean ± S.E.M., immuno-blot analysis are 
shown as mean ± S.E.M. after densitometric image analysis (ImageJ software, National 
Institute of Mental Health, Bethesda, Maryland, USA). Unpaired Student’s t-test was 
performed and p-values < 0.05 were considered significant.  
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Results 
Increased basement membrane thickness in human tissue sections from the lung of 
asthma patients 
Superficial endobronchial biopsy specimens were stained using Harris’s haematoxylin and 
alcoholic eosin and light microscopic photographic images were recorded. Figure 1 
presents a typical example of a human airway tissue cross-section demonstrating the 
increased thickness of the basement membrane present in asthmatics (Figure 1B) relative 
to non-asthma (Figure 1 A) patients.   
 
Figure 1: Light microscopic images of airway tissue sections obtained from a non-asthma (A) and an 
asthma (B) patient. Images (magnification 60x) are representative of tissues obtained from 3 non-asthmatic 
and 9 asthmatic patients stained with Haematoxylin-Eosin. Note the increased thickening of the basement 
membrane in the asthmatic airways. E = epithelium, arrows are indicating the basement membrane. 
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Hypoxia reduced proliferation of BSMC of asthmatic and non-asthmatic subjects 
BSMC obtained from asthmatic (n = 4) and non-asthmatic (n = 5) subjects were cultured 
for 72 hours under either normoxic (21% O2) or hypoxic conditions (5% and 1% O2) in 
presence and absence of 5% FCS. As shown in Figure 2A, under normoxic conditions and 
in the presence of 5% FCS, BSMC numbers significantly increased in both the asthmatic 
group (2.08 ± 0.13-fold) and the non-asthmatic group (1.85 ± 0.13-fold). Although BSMC 
of asthmatics proliferated slightly faster, the fold-increase between asthma and non-asthma 
was not significantly different (p = 0.21). In the presence of FCS, moderate hypoxia (5% 
O2) significantly reduced cell numbers of asthmatics only to 1.62 ± 0.12-fold (p < 0.05). 
Severe hypoxia (1% O2) did not further reduce BSMC proliferation of asthmatics 
(1.65 ± 0.14-fold), but a similar significant reduction of proliferation was observed in 
BSMC of non-asthmatics to 1.30 ± 0.13-fold; p < 0.05). In the absence of FCS, BSMC did 
not proliferate and hypoxia (1% O2) did not have any effect (Figure 2B). As shown in 
Figure 2C- 2F, under hypoxic conditions the proliferation markers PCNA and cyclin E 
were both significantly down regulated (PCNA: 56 ± 1% compared to normoxia, p < 0.001 
and cyclin E: 84 ± 5% compared to normoxia, p < 0.05). No differences were observed 
between the asthmatic and non-asthmatic group. 
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Figure 2: Proliferation characteristics of BSMC from asthmatic (A) and non-asthmatic (NA) subjects 
in the presence of 1%, 5% and 21% O2 (72 h). BSMC were cultured for 72 hours in presence (A) and 
absence (B) of 5% FCS. n = 12 (6A/6NA) for 21% and 1% O2 and n = 7 (4A/3NA) for 5% O2. C and D, 
show the densitometric analysis of effects on hypoxia (1% O2) relative to normoxic conditions (21% O2) for 
PCNA (n = 9) and cyclin E (n = 6). Representative Western blots for PCNA and cyclin E protein expression 
are demonstrated in the lower panel (E and F). Values are given as mean ± S.E.M.. * :  p-value ≤ 0.05, 
** :  p-value ≤ 0.01, *** :  p-value ≤ 0.001. 
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Hypoxia induced HIF-1α in BSMC 
To study whether hypoxia was associated with the induction of HIF-1α, BSMC (n = 5) 
were cultured in the presence of 5% FCS and under normoxic (21% O2), or stringent 
hypoxic conditions (1% O2). As demonstrated in Figure 3, normoxic conditions did not 
induce HIF-1α. In contrast, HIF1-α was transiently induced and peaked after 4 hours in 
BSMC under stringent hypoxic conditions. Extended exposure to hypoxic conditions (24 
and 48 h) HIF-1α levels decreased, but did not return to control levels. Cobalt chloride, a 
chemical inhibitor of the prolyl-hydroxylase that targets HIF-1α for proteasomal 
degradation under normoxic conditions, was used as a positive control (50 and 100 μM). 
 
Figure 3: Western blot analysis detecting HIF-1α and GAPDH (loading control) in lysates of BSMC. 
Cell were incubated under 1% and 21% O2 for 4, 24 and 48 h (indicated at top). CoCl2 was used as positive 
control to stabilize HIF-1α protein. In contrast to CoCl2, which has a transient effect only, hypoxia induced a 
prolonged expression of HIF-1α. Experiment shown is representative for 5 independent experiments. The 
right hand panel (showing the 24 h and 48 h expression levels of HIF-1α) was obtained after longer exposure 
of the same blot, which contained all samples.  
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Hypoxia induced IL-6, IL-8 and VEGF, but not ENA-78 
Next, we studied the effect of hypoxia on the release of four pro-angiogenic/pro-
inflammatory cytokines: IL-6, IL-8, VEGF and ENA-78. BSMC obtained from asthmatic 
(n = 5) and non-asthmatic (n = 5) subjects were cultured for 72 h under either normoxic 
(21% O2) or stringent hypoxic conditions (1% O2) in presence or absence of 5% FCS. In 
the absence of FCS, hypoxia significantly increased the release of VEGF protein in both 
asthmatic and non-asthmatic cells (8.62 ± 2.86-fold and 9.88 ± 2.79-fold; both p < 0.05; 
Figure 4A). Similarly, under the same conditions the release of IL-6 protein increased in 
both asthmatic and non-asthmatic cells (5.42 ± 1.29-fold and 5.34 ± 1.18-fold; both 
p < 0.05; Figure 4B). The effect of hypoxia on the release of IL-8 was less pronounced, but 
significant (2.72 ± 0.63-fold and 1.98 ± 0.29-fold; both p < 0.05; Figure 4C).   
In the presence of 5% FCS, hypoxia significantly increased the release of VEGF protein by 
both asthmatic and non-asthmatic cells (6.37 ± 0.96-fold and 6.54 ± 1.74-fold; both 
p < 0.05; Figure 4A). Under the same conditions the release of IL-6 protein increased in 
both asthmatic and non-asthmatic cells (2.36 ± 0.59-fold and 3.03 ± 0.76-fold; both 
p < 0.05; Figure 4B). In the presence of FCS, hypoxia did not affect the release of IL-8 
(Figure 4C). Furthermore, did hypoxia not affect the release of ENA-78 significantly 
(0.88 ± 0.24-fold, p = 0.59). No significant differences were observed between asthmatic 
and non-asthmatic BSMC in any condition.  
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Figure 4: Chemokine release from BSMC grown under hypoxic conditions (1% O2, 72 h) compared to 
normoxic conditions. Concentrations of VEGF (A), IL-6 (B) and IL-8 (C) in CM collected from BSMC 
(n=10, 5A/5NA) were determined by ELISA. Values are given as mean ± S.E.M.. * :  p-value ≤ 0.05, 
** :  p-value ≤ 0.01, *** :  p-value ≤ 0.001. 
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Increased angiogenic potential of BSMC grown under hypoxic conditions is reversed 
by anti-VEGF and SB265610 
The angiogenic potential of CM collected from BSMC grown under hypoxic (1% O2) and 
normoxic (21% O2) conditions was examined using the EC-spheroid in vitro angiogenesis 
assay. Spheroids were also cultured in unconditioned medium (i.e. with medium that had 
not been included with BSMC) to control for “spontaneous” sprout outgrowth. Figure 5 
shows representative images of spheroids incubated with CM from BSMC grown under 
normoxic (left panel) or hypoxic (right panel) conditions (Figure 5A). The quantitation of 
sprout outgrowth as the mean tubule length/spheroid after a 24 h culture period is shown in 
Figure 5B. CM of BSMC cultured under hypoxic conditions significantly increased the 
sprout formation compared to CM of BSMC grown under normoxic conditions 
(53,7 ± 2.4 µm vs. 73.0 ± 4.5 µm; p < 0.001; n = 3).  
Finally, we sought to define a mechanism involved in the aforementioned findings. Since 
IL-8 signals through the chemokine receptor CXCR2, we studied the effects of a 
competitive CXCR2-selective antagonist SB 265610 (10 nM) and a neutralizing anti-
VEGF antibody (0.2µg/ml) in the EC-spheroid in vitro angiogenesis assay. We examined 
the effect of hypoxia on pooled CM, derived from asthmatics and non-asthma controls. 
CM from non-asthma controls did not show any difference whether BSMC were grown 
under hypoxic or normoxic conditions. In contrast, CM from asthmatics significantly 
increased the sprout outgrowth from EC spheroids comparing normoxia 
(42.83 ± 11.06 µm) and hypoxia (69.39 ± 9.22 µm; p < 0.001). As demonstrated in Figure 
5C, SB 265610 and anti-VEGF significantly reduced CM-induced EC-sprouting (SB 
265610: 51.31 ± 9.77 µm, p < 0.05; anti-VEGF 34.33 ± 7.09 µm, p < 0.001). 
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Figure 5: . In vitro angiogenesis assay. A, Representative images of the in vitro angiogenesis assay showing 
sprout outgrowth from EC-spheroids incubated with CM from BSMC cultured in presence of 21% O2 
(normoxia) or 1% O2 (hypoxia). B, Lengths of sprouts outgrowing from every spheroid were measured and 
the mean of the longest 10 sprouts of 7 randomly chosen spheroids was plotted. C, shows the effects of the 
CXCR2-blocker SB 265610, anti-VEGF, and the combination of SB 265610 plus anti-VEGF on EC-
sprouting using the in vitro angiogenesis assay. EC-sprouting was induced by pooled CM of BSMC (n=5) 
cultured under hypoxic conditions (1% O2, 72 h). Values are given as mean of the mean ± S.E.M.. 
* :  p-value ≤ 0.05, ** :  p-value ≤ 0.01, *** :  p-value ≤ 0.001. 
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Discussion 
Hypoxia of the airways can be caused by a range of mechanisms, including diminished 
ventilation drive, airway obstruction, intra-alveolar exudates, airway wall inflammation, as 
well as fibrosis and basement membrane thickening [25]. The latter is one of the striking 
features of the asthmatic airway wall and may well contribute to locally restricted hypoxia. 
This may in turn affect the properties of resident cells present in the airway wall. Biopsy 
studies in adults and children showed a significant increase in the number of microvessels 
present in the airway wall of asthma patients and there is evidence that endothelial cells 
undergo proliferation [26-28]. In our current study, we showed that hypoxia has a profound 
effect on the proliferation of and angiogenic factors release by primary human BSMC of 
asthmatic and non-asthmatic subjects.  
First, hypoxia has the capacity to significantly reduce the proliferation rate of BSMC of 
both asthmatic and non-asthmatic subjects. Importantly, a significantly reduced 
proliferation of BSMC of asthma patients was observed in the presence of 5% O2, whereas 
the same conditions did not affect BSMC of control subjects. Stringent hypoxic conditions 
(1% O2) significantly reduced the proliferation of BSMC from asthmatics and non-
asthmatics. This indicates that BSMC of asthmatics are more prone to hypoxic (culture) 
conditions. The reason for this difference is unclear, but it might reflect diminished 
proliferation control responses as observed in cultured asthmatic BSMC [2-5, 29]. The 
reduced proliferation under stringent hypoxic conditions (1% O2) was confirmed by lower 
levels of PCNA- and cyclin E proteins in BSMC of asthmatic and non-asthmatic subjects. 
Our data also indicate that the effects of hypoxia may be distinct in different model 
organisms, since it has been demonstrated that BSMC of rats have significantly increased 
proliferation rates under hypoxic conditions [30]. The reason for this discrepancy between 
primary human BSMC and those of rats is currently not known. 
Second, our study showed that hypoxia enhanced the release of VEGF, a mediator of 
microvascular leakage, EC proliferation and vascular remodeling, as well as IL-6 and IL-8, 
which are known to be involved in angiogenesis [31-33]. The mechanisms underlying 
airway wall remodeling present in the lungs of asthma patients, which also involve 
angiogenesis of the airway wall, are complex and incompletely understood. Hypoxia may 
trigger the BSMC to express HIF-α, a transcription factor critically involved in the 
regulation of several pro-inflammatory and pro-angiogenic factors. VEGF and HIF-α are 
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expressed in the airways and airway lining fluids of asthma patients, suggesting that both 
factors may play and important role in inflammation as well as vascular remodeling in 
asthma [34, 35]. The observed increased number of microvessels present in the airway wall 
of patients with asthma [26-28], may be explained by  the significant higher levels of 
VEGF and increased HIF expression in the sub-epithelial cell layers of asthma patients 
relative to healthy controls [14]. It is important to note that high expression of VEGF was 
reported in the airways of asthma patients [35, 36].  
Our results demonstrated that hypoxia transiently induced HIF-1α protein expression in 
BSMC, with no differences between cells of asthmatic and non-asthmatic subjects. The 
expression of HIF-1α, the hypoxia-induced subunit of the hypoxia inducible factor (HIF), 
was transient and optimal after 4 hours, indicating that the effects on the release of VEGF, 
IL-6 and IL-8 might be via this transcription factor. CM isolated from BSMC cultured 
under hypoxic conditions demonstrated a significantly increased endothelial sprout 
outgrowth relative to CM of BSMC grown under normoxic conditions, confirming that 
BSMC cultured under hypoxic conditions induced the release of pro-angiogenic factors. 
Indeed, our blocking experiments using SB265610 and/or anti-VEGF demonstrated both 
the involvement of CXCR2 signaling and VEGF in the angiogenic process. 
Previously, we showed that BSMC isolated from asthma patients exhibit increased 
angiogenic potential, which associated with increased productions of CXCR2 ligands 
(ENA78, GRO-α and IL-8) and VEGF [unpublished data, manuscript submitted]. Our 
present study showed that hypoxia predominantly induced VEGF and IL-6, whereas IL-8 
was only 2-fold increased and ENA-78 not affected. It has been observed that hypoxia 
regulates VEGF activities mainly through transcriptional repression of the neutropilin-2 
receptor [37]. Furthermore, increased levels of IL-6 and IL-8 have been reported in asthma 
patients. [38]. The involvement of HIF-1α in the increased release of IL-6 and IL-8 is 
largely unknown, although both genes are associated with hypoxia-inducible promoter 
and/or enhancer sequences [own observations after checking the annotated sequences with 
GENE tools]. This suggests that hypoxia may exert differential effects on different 
cytokines via distinctly different mechanisms.  
In conclusion, hypoxia has dualistic effect on proliferative and inflammatory responses of 
both healthy and asthmatic primary human BSMC. Our data imply that hypoxia cannot be 
a direct cause for the observed increased smooth muscle mass in the airway wall of asthma 
patients. Rather, these cells start to elicit a range of pro-inflammatory cytokines and growth 
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factors that intensify airway wall inflammation and remodeling through advancing the 
process of neovascularization.  A novel strategy to counteract airway wall remodeling may 
therefore be found in the development of drugs that counteract the process of 
neovascularization. Both, BSMC and EC, are therefore promising new targets to counteract 
and/or alleviate airway wall remodeling.  
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Abstract 
Background: Bronchial smooth muscle cells (BSMC) are a major source of pro-
inflammatory and pro-angiogenic cytokines and chemokines, including VEGF and CXC-
chemokines. CXC-chemokines act primarily on neutrophils, mediating their recruitment to 
and activation at the side of inflammation. In humans, house-dust mite (HDM) allergens 
can cause asthmatic exacerbations and trigger an inflammatory response through protease-
dependent mechanisms.  
Objective: We investigated the effect HDM extract on the release of pro-angiogenic and 
pro-inflammatory cytokines from BSMC. 
Methods: Human primary BSMC were stimulated with HDM extract in the absence or 
presence of fetal calf serum (FCS). Twenty angiogenic cytokines were detected by a 
specific antibody array and modified protein levels were confirmed by ELISA. Neutrophil 
migration was detected using a 96-well Boyden chamber. 
Results: The concentration of ENA-78 in conditioned medium collected from BSMC 
stimulated with HDM extract was significantly reduced, whereas ENA-78 mRNA levels 
were not altered. In the presence of 5% FCS the inhibitory effect of HDM on ENA-78 
expression was abrogated. Furthermore, recombinant ENA-78 was degraded by incubation 
with HDM extract, which was prevented by addition of FCS as well as by addition of a 
serine protease inhibitor. Neutrophil migration towards recombinant ENA-78 was reduced 
in HDM extract-stimulated conditions.  
Conclusion: HDM proteases degrade ENA-78. Thus exposure to HDM allergens may alter 
ENA-78 levels in the lungs and may affect angiogenesis and the inflammatory response in 
the airways of asthma patients.    
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Introduction 
House dust mites (HDM; Dermatophagoides pteronissinus) allergens are among the most 
potent stimuli of asthma attacks [1, 2]. HDM excretions contain a plethora of biologically 
active compounds, which have allergenic potential that prompts IgE response in sensitized 
subjects. The same HDM compounds also have pro-inflammatory properties, which are 
independent of the IgE response. In asthma, neoangiogenesis of the airway wall is a 
recently recognized pathology, which contributes to airway wall thickness [3-5]. There is 
also evidence from animal models that HDM and other allergens can induce 
neovascularization of the inflamed airway [6, 7]. However, the effect of HDM allergens on 
asthma related angiogenesis remain incompletely understood. 
HDM extracts have been shown to disrupt the tight-junctions between epithelial cells and 
lead to the complete desquamation of the epithelial cell layer, hence facilitating the passage 
of allergens across the epithelial air-tissue border [8-10]. The major HDM allergen, Der p1, 
is a cysteine protease [11-13] and may be responsible for the observed epithelial cell 
desquamation, for the release of cytokines, and facilitates the transport of allergens across 
cultured epithelial cell layers [9-11, 14-16]. In consequence, the desquamation of the 
protective epithelium may allow allergenic compounds to penetrate deeper into the airway 
wall, thereby facilitating airway hyper-sensitization.  
Proteases present in HDM excrements also exerted a direct modulatory effect on regulatory 
proteins in cultured human bronchial smooth muscle cells (BSMC) that affect the cell’s 
ability to proliferate and to secrete cytokines [17]. In particular, BSMC exposed to HDM 
extract increased interleukin (IL)-6 release and cell proliferation through the protease-
activated receptor (PAR)-2 [17]. Hence, HDM exposure contributes to inflammation and 
airway wall remodeling in a mechanism independent of the immune system by direct 
interaction with BSMC. Furthermore, proteolytic activities present in fungal and bacterial 
extracts have been shown to specifically and dose-dependently degrade human interleukin 
(IL)-6 and IL-8 [18], as well as RANTES, monocyte chemotactic protein (MCP)-1 and 
epithelial-derived neutrophil attractant (ENA)-78 [19], hence reducing the bio-availability 
of these cytokines.   
Together, these data imply that the exposure of the airways to external factors with intrinsic 
proteolytic activity affects the relative level of immuno-modulatory cytokines, which may 
affect inflammation and microvessel formation and airway remodeling. In the present 
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study we analyzed the effect of HDM extract on the release and degradation of a panel of 
cytokines that have pro-inflammatory and angiogenic activity and are implicated in airway 
wall remodeling. Our data show that the proteolytic activity present in HDM extract 
degraded ENA-78 and reduced the migration of neutrophils. These findings imply that 
HDM allergens may have the capacity to modify the development of an eosinophil 
dominated inflammatory response in the lung. 
  
  ENA-78 IS DEGRADED BY HDM EXTRACT DERIVED PROTEASES 
 
111 
Methods  
Isolation of primary bronchial smooth muscle cells  
BSMC were obtained from endobronchial biopsies obtained by flexible bronchoscopy or 
from therapeutically resected bronchial tissue obtained from the Department of Internal 
Medicine, Pneumology (University Hospital Basel, Basel, Switzerland) with the approval 
of the local ethical committee (EK:05/06) and written informed consent of all patients. 
Isolation of BSMC was performed as described earlier [20, 21]. BSMC bundles were 
dissected from the surrounding tissue by microscopy and pure muscle bundles were plated 
in a 25 cm
2
-flask pre-wetted with 1 ml of Dulbecco`s modified Eagle`s medium (DMEM) 
containing GlutaMax-I 4.5 g/l glucose (Gibco
®
, Bioconcept, Allschwil, Switzerland), 5% 
FCS, 1x antibiotics-antimycotics, and 1x modified Eagle`s medium vitamin mix 
(Invitrogen, Lubio, Luzern, Switzerland). BSMC were characterized by immunostaining as 
described earlier [22]. 
Generation of conditioned medium (CM)  
BSMC were grown in BSMC-growth medium (GM): RPMI 1640 supplemented with 5% 
fetal calf serum (FCS), 8 mM L-glutamine, 20 mM hydroxyethyl piperazine ethane 
sulfonic acid, 1x antiobiotics-antimycotics and 1x modified Eagle’s medium vitamin mix 
(Invitrogen, Lubio, Luzern, Switzerland) under normoxic conditions (21% O2, 5% CO2, 
37°C) BSMC were seeded and kept in BSMC-GM for 24 h before they were serum-
deprived for 24 h prior to stimulation. A stock solution (1 mg/ml) of HDM extract (ALK-
Abello, Hørsholm, Denmark) was prepared  in RPMI 1640 medium and diluted in RPMI 
1640 to the final concentration (20, 10 and 2 µg/ml), which was then sterilized by filtration 
(0.22 m) (MN Sterilizer PES; Macherey-Nagel AG, Oensingen, Switzerland). 10 ng/ml of 
Colistin (Roth, Arlesheim, Switzerland) was to avoid effects of lipopolysaccharids (LPS) 
in HDM extract. To obtain HDM-CM, BSMC were incubated for 24 and 72 h (37°C) with 
HDM extract (2 and 10 µg/ml) or without HDM extract in the presence or absence of 5% 
FCS. 
Angiogenesis Antibody Array  
The Human Angiogenesis Antibody Array G 1000 (Raybiotech, Lucerna-Chem, Luzern, 
Switzerland) was used to detect the release of 20 angiogenesis-related cytokines and 
growth factors in CM obtained from BSMC stimulated with HDM extract or unstimulated 
BSMC. 100 µl of undiluted CM collected after 72 h were applied to each array and the 
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angiogenesis-related factors were evaluated according to the manufacturer instructions. 
Cy3 fluorescence was measured by a NimbleGen MS 200 microarray Scanner (Roche, 
Basel, Switzerland) and signal intensity was analyzed by AIDA software (Raytest, 
Straubenhardt, Germany).  
Cytokine-ELISA  
Enzyme linked immunosorbent assay (ELISA) kits for IL-8, ENA-78 and VEGF were 
purchased from R&D (Abingdon. UK) and ELISA were performed according to the 
manufacturer´s instructions. 100 µl of CM obtained from BSMC were measured undiluted 
(VEGF), 1:5 diluted (ENA- 78) or 1:50 diluted (IL-8). 
ENA-78 mRNA expression by RT-PCR  
BSMC were grown in absence and presence of HDM extract (20 µg/ml) for 6 h. Total 
RNA was extracted from 10
6
 cells (t = 0 h, and t = 6 h) by Trizol method (Gibco
®
, 
Bioconcept, Allschwil, Switzerland). Then, 5 µg of total RNA were converted into cDNA. 
Semi-quantitative PCR (94°C, 65°C, 72°C) was performed for 28 cycles using a Thermo 
Hybaid PCR Express (Catalys, Wallisellen, Switzerland) as described elsewhere [23]. The 
primers for ENA-78 were: forward: 5’-ATC TCC GCT CCT CCA CCC AGT-3’ and 
reverse: 5’-TTC TTG TCT TCC CTG GGT-3’ generating a PCR fragment of 493 bp. The 
primers GAPDH were: forward 5’-CCA AAG GGT CAT CAT CTC TGC-3’ and GAPDH 
reverse: 5’-ATT TGG CAG GTT TTT CTA-3’ generating a PCR fragment of 417 bp. 
Polymorphonuclear cells (PMNC) isolation and neutrophil chemotaxis  
Anti-coagulated blood was obtained from the local blood bank (Blutspendezentrum Basel; 
Switzerland) after written informed consent of all donors. PMNC were isolated using 
Polymorphprep
TM
 separation medium as recommended by the manufacturer (Axis-Shield, 
Axonlab, Baden, Switzerland). Chemotaxis was assessed using 96-well Boyden chamber 
(Neuroprobe, Gaithersburg, USA) as previously described [24]. The lower compartments 
of the 96-wells chamber were filled with either 100 ng/ml recombinant ENA-78, or 10 
ng/ml recombinant ENA-78 (stimulated for 24 h with or without 10 µg/ml HDM extract), 
or 10µg/ml HDM extract in RPMI 1640, or RPMI 1640 alone, and then covered with a 5 
μm pore-sized polycarbonate filter (Neuroprobe, Gaithersburg, USA). Next, 200 µl of 
neutrophil suspension (2x10
6
 cells/ml) was added to the upper compartments. After 2 h of 
incubation (37°C, 5% CO2) the upper compartment was removed, the filter was fixed and 
stained with Differential Quik Staining Kit (Polyscience, Brunschwig, Basel, Switzerland). 
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The membrane was scanned with a desktop scanner, and the intensity of spots was 
analyzed using Image J software. 
Statistics  
Cytokine data are presented as mean ± S.E.M. Migration analysis is shown as mean ± 
S.E.M. after densitometric image analysis (ImageJ software, National Institute of Mental 
Health, Bethesda, Maryland, USA.). Unpaired Student’s t test was performed and p-values 
< 0.05 were considered significant.   
ENA-78 IS DEGRADED BY HDM EXTRACT DERIVED PROTEASES   
 
114 
Results 
HDM extract down-regulated ENA-78 protein levels 
To identify proteins that are affected by the addition of HDM extract to BSMC, CM of 
stimulated and unstimulated BSMC were applied to an antibody array. Comparing the 
protein expression pattern by the angiogenesis array the expression of ENA-78 was 
reduced in CM collected from BSMC that had been stimulated with HDM extract (Figure 
1A and 1B). The panel of pro-angiogenic proteins of the array is shown in Figure 1C. We 
then confirmed this finding with an ENA-78 ELISA in CM collected from BSMC 
stimulated with HDM extract for 24 and 72 h. As shown in Figure 1D, HDM extract (10 
µg/ml) significantly decreased the concentration of ENA-78 in CM of stimulated BSMC 
(p < 0.05; n = 10). In contrast, HDM extract (10 µg/ml) did not significantly alter the levels 
of other cytokines such as IL-8 or VEGF (data not shown).  
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Figure 1: Effect of HDM extract on the release of angiogenic factors. A and B, show representative 
images of two angiogenesis antibody arrays incubated with CM collected from BSMC either unstimulated 
(A) or stimulated with 10 µg/ml HDM extract (B) for 72 h. C, provides the respective antibody array map for 
panels A and B. Standard abbreviations for the detected proteins are used, Pos: positive control, Neg: 
negative control, IC1-IC3: internal controls 1-3. D, Dose-dependency of reduced ENA-78 concentration in 
CM from BSMC (n = 10) stimulated with HDM extract (2 or 10 µg/ml). CM was collected after 24 and 72 h. 
Asterisk indicate statistic significant difference of HDM stimulated BSMC compared to unstimulated cells: 
**p < 0.005, *** p < 0.001.  
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HDM extract did not affect ENA-78 mRNA levels 
To determine whether the HDM-dependent reduction of ENA-78 protein levels were 
associated with reduced gene transcription RT-PCR was performed using total RNA 
extracted after 0 and 6 h from BSMC grown in the absence and presence of HDM extract 
(20 µg/ml). As shown in Figure 2, exposure to HDM extract did not significantly affect 
RNA levels of ENA-78.  
 
Figure 2 Detection of ENA-78 by RT-PCR. A, ENA-78 mRNA expression (fragment size: 493 bp) in an 
agarose-gel-electrophoresis. GAPDH (fragment size: 417 bp) served as internal control. S1/S2: subject 1/2. 
B, Densitometric analysis of RT-PCR as mean ± S.E.M (n = 2) 
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HDM extract specifically degraded ENA-78 protein 
The observation that HDM extract stimulation decreased ENA-78 protein levels, while 
ENA-78 mRNA levels were unchanged indicated that the ENA-78 protein may be 
degraded by proteolytic activities of the HDM extract. Therefore, we incubated BSMC 
with 5% FCS which has strong anti-proteolytic activity in the presence of HDM extract (2 
and 10 µg/ml). As shown in Figure 1D, HDM extract reduced the ENA-78 protein level in 
CM collected from BSMC. In the presence of 5% FCS this effect was completely 
abrogated (Figure 3A), suggesting a protease-dependent mechanism of ENA-78 
degradation.  
Next, we tested the effect of HDM extract on the basal concentration of ENA-78 in CM 
from BSMC (n = 7) grown in the absence of FCS for 24 and 72 h. After collection of the 
CM, we incubated with either HDM extract alone or a combination of HDM extract + 5% 
FSC. In the absence of FCS, the addition of HDM extract significantly reduced the basal 
concentration of ENA-78 in CM. FCS abrogated this effect (Figure 3B). We confirmed the 
proteolytic activity of HDM extract and the anti-proteolytic effect of FCS on ENA-78 
degradation with recombinant ENA (data not shown). Furthermore, we assessed the effect 
of the serine protease inhibitor AEBSF and the cysteine protease inhibitor E64 on the 
degradation of recombinant ENA-78 by HDM extract. Incubation with E64 (0.5 µM, 5 
µM, 10 µM) did not prevent ENA-78 degradation by HDM extract in any of the used 
concentrations (data not shown). In contrast, the addition of AEBSF led to a significant 
increase in ENA-78 concentration compared to control condition (without AEBSF) (Figure 
3C). 
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Figure 3: Effect of FCS and HDM extract (2 or 10 µg/ml) on ENA-78 concentration: A, in CM of 
BSMC cultured in the presence of 5% FCS after 24 and 72 h. B, of CM derived from BSMC cultured in the 
absence of FCS (n = 5) stimulated with HDM extract in the absence (left panel) or presence (right panel) of 
5% FCS. *** indicate statistical significant differences with p < 0.001 comparing HDM extract stimulated 
CM to unstimulated CM. C, Degradation of recombinant ENA-78 by HDM extract is inhibited by the 
addition of the serine proteases inhibitor AEBSF or FCS. Bars represent the mean ± S.E.M, n = 3. *** 
indicate statistical significant differences with p < 0.001 comparing the rescue effect of AEBSF on HDM 
extract-induced ENA-78 degradation. 
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HDM-CM reduced chemotaxis of neutrophils 
Finally, we tested the effect of HDM extract-dependent ENA-78 degradation in regard to 
the chemotactic capacity of ENA-78. As shown in Figure 4 ENA-78 alone dose-
dependently induced neutrophil migration compared to medium only, while HDM extract 
alone had no significant effect on the induction of migration. When combined HDM 
extract reduced the neutrophil migratory effect of ENA-78.  
 
 
  
Figure 4: Densitometric analysis 
of neutrophil migration. 
Migrated cells were stained with 
Diff Quik staining kit, scanned 
with a desktop scanner and 
densitometric analysis was 
performed with Image J. Values 
are expressed as mean ± S.E.M., 
** p < 0.005, n = 3 (neutrophils 
from 1 healthy subject in 
triplicate).  
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Discussion 
In our study, we demonstrated for the first time that the CXCR2 ligand ENA-78 was 
degraded upon exposure to HDM extract, whereas a second CXCR2 ligand IL-8 was not 
affected. CXCR2 ligands have been suggested to play a crucial role in inflammation and 
angiogenesis, in particular in directing neovascularization in tumors [25].  
We recently showed that angiogenic CXCR2 ligands are produced by human BSMC 
directing sprout outgrowth from endothelial cell spheroids [unpublished data, manuscript 
submitted]. In addition to its angiogenic characteristics, ENA-78 exerts strong chemotactic 
properties for neutrophils [26]. Several neutrophil attracting chemokines are present in the 
lung, including IL-8, growth related proteins (GRO-α, β, γ) and ENA-78 [27, 28]. 
Although ENA-78 and IL-8 share some properties, each cytokine has its own specific 
effects [29-33]. Comparing these studies, ENA-78 seems to be more important in chronic 
than in acute immunological responses. 
The observation that FCS completely blocked the degradation of ENA-78 protein 
demonstrated that the degradation was due to the proteolytic activity present in the HDM 
extract and this was confirmed by the protective effect of the serine protease inhibitor 
AEBSF. In contrast, the cysteine protease inhibitor E64 did not prevent HDM extract-
dependent ENA-78 degradation, therefore we conclude that one mechanism of ENA-78 
degradation is dependent on serine proteases present in HDM extract. Proteolytic activities 
present in HDM extracts have been extensively studied and several HDM allergens have 
been identified as proteases [34]. A major effect of these proteases is the selective 
reduction of the bio-availability of cytokines, since not all cytokines are equally prone to 
proteolytic degradation [19]. Diminished bio-availability of cytokines due to proteolytic 
degradation has been associated with opportunistic fungi, in particular Aspergillus 
fumigatus [18], as well as with pathogenic bacteria, such as Pseudomonas aeruginosa [19]. 
Characteristic for both organisms is the secretion of a wide range of proteolytic enzymes 
intended for growth and existence. The cytokine-degrading properties of the proteases 
produced by these organisms do not only alter the relative amounts of disease relevant 
immunomodulatory cytokines in the airways, they may also help the organisms to invade 
the lung. Proteolytic modifications of ENA-78 protein have been shown to reduce and to 
enhance its biological activity. Cleavage of ENA-78 by MMP, MMP2, or by the 
aminopeptidase CD13 have been shown to enhance its activity [35, 36], whereas 
proteolytic modifications caused by metalloproteases from Pseudomonas aeruginosa was 
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accompanied by the loss of chemotactic activity [19]. We were able to provide evidence 
that proteolytic modifications by HDM extract abrogate the neutrophil-attracting properties 
of ENA-78. 
Our data provide evidence that HDM proteases may directly affect the pro-inflammatory 
and pro-angiogenic cytokine response through proteolytic degradation of ENA-78 protein. 
Produced by epithelial cells, ENA-78 was first described as a chemo-attractant for 
neutrophils [31]. We have recently reported that not only epithelial cells but also BSMC 
release high levels of ENA-78 [unpublished data, manuscript submitted]. Continuous 
exposure to HDM allergens may reduce the bioavailability of ENA-78 due to proteolytic 
degradation, and lower the number of neutrophils that infiltrate the asthmatic airway. This 
may alter the immune response in favor of eosinophilic inflammation, as it is often 
observed in the lungs of asthmatic patients, and thought of as the main histopathology of 
the asthmatic lung [37-40]. It should be noted, however, that asthma sometimes is 
associated with neutrophilia. In a sheep model of asthma HDM extracts induced neutrophil 
infiltration at 6 h, followed by eosinophils and activated lymphocytes into the lung tissue 
and BAL, similar to the late-phase allergic response seen in human asthma [41]. 
It is currently unknown whether or not an association exists between exposure to HDM 
allergens and eosinophilia. However, selective degradation of ENA-78 by proteases 
present in HDM extract might provide a partial explanation.  
Our experiments with the Boyden chamber showed that chemotactic migration of 
neutrophils towards ENA-78 is reduced in the presence of HDM extract. The 
microenvironment, the relative presence and balance of cytokines and chemotactic factors, 
ultimately determines the immunological response. Disturbance of the equilibrium 
between proteases and anti-proteases is a common pathological feature of inflammatory 
airway diseases. An external addition of foreign proteases, which may be derived from 
fungi, bacteria or HDM, may distort this intricate balance and lead to irreversible 
impairment of airway function.    
Taken together, our data demonstrate that the ENA-78 protein is susceptible to degradation 
by proteases present in HDM extract. Although reduced bioavailability of ENA-78 could 
potentially cause atypical immunological characteristics in vivo, the biological relevance of 
this observation remains to be established.  
ENA-78 IS DEGRADED BY HDM EXTRACT DERIVED PROTEASES   
 
122 
References 
1. Nelson RP, Jr., DiNicolo R, Fernandez-Caldas E, Seleznick MJ, Lockey RF, Good RA. Allergen-
specific IgE levels and mite allergen exposure in children with acute asthma first seen in an emergency 
department and in non-asthmatic control subjects. The Journal of allergy and clinical immunology. 
1996;98(2):258-63. 
2. Thomas WR, Hales BJ, Smith WA. House dust mite allergens in asthma and allergy. Trends in 
molecular medicine. 2010;16(7):321-8. 
3. Al-Muhsen S, Johnson JR, Hamid Q. Remodeling in asthma. The Journal of allergy and clinical 
immunology. 2011;128(3):451-62; quiz 63-4. 
4. Detoraki A, Granata F, Staibano S, Rossi FW, Marone G, Genovese A. Angiogenesis and 
lymphangiogenesis in bronchial asthma. Allergy. 2010;65(8):946-58. 
5. Wilson JW, Kotsimbos T. Airway vascular remodeling in asthma. Current allergy and asthma 
reports. 2003;3(2):153-8. 
6. Van der Velden J, Barker D, Barcham G, Koumoundouros E, Snibson K. Increased vascular density 
is a persistent feature of airway remodeling in a sheep model of chronic asthma. Experimental lung research. 
2012;38(6):307-15. 
7. Avdalovic MV, Putney LF, Schelegle ES, Miller L, Usachenko JL, Tyler NK, et al. Vascular 
remodeling is airway generation-specific in a primate model of chronic asthma. American journal of 
respiratory and critical care medicine. 2006;174(10):1069-76. 
8. Wan H, Winton HL, Soeller C, Gruenert DC, Thompson PJ, Cannell MB, et al. Quantitative 
structural and biochemical analyses of tight junction dynamics following exposure of epithelial cells to house 
dust mite allergen Der p 1. Clinical and experimental allergy : journal of the British Society for Allergy and 
Clinical Immunology. 2000;30(5):685-98. 
9. Wan H, Winton HL, Soeller C, Tovey ER, Gruenert DC, Thompson PJ, et al. Der p 1 facilitates 
transepithelial allergen delivery by disruption of tight junctions. The Journal of clinical investigation. 
1999;104(1):123-33. 
10. Winton HL, Wan H, Cannell MB, Gruenert DC, Thompson PJ, Garrod DR, et al. Cell lines of 
pulmonary and non-pulmonary origin as tools to study the effects of house dust mite proteinases on the 
regulation of epithelial permeability. Clinical and experimental allergy : journal of the British Society for 
Allergy and Clinical Immunology. 1998;28(10):1273-85. 
11. Simpson RJ, Nice EC, Moritz RL, Stewart GA. Structural studies on the allergen Der p1 from the 
house dust mite Dermatophagoides pteronyssinus: similarity with cysteine proteinases. Protein sequences & 
data analysis. 1989;2(1):17-21. 
12. Chua KY, Stewart GA, Thomas WR, Simpson RJ, Dilworth RJ, Plozza TM, et al. Sequence analysis 
of cDNA coding for a major house dust mite allergen, Der p 1. Homology with cysteine proteases. The 
Journal of experimental medicine. 1988;167(1):175-82. 
13. Hewitt CR, Horton H, Jones RM, Pritchard DI. Heterogeneous proteolytic specificity and activity of 
the house dust mite proteinase allergen Der p I. Clinical and experimental allergy : journal of the British 
Society for Allergy and Clinical Immunology. 1997;27(2):201-7. 
14. King C, Brennan S, Thompson PJ, Stewart GA. Dust mite proteolytic allergens induce cytokine 
release from cultured airway epithelium. J Immunol. 1998;161(7):3645-51. 
15. Robinson C, Kalsheker NA, Srinivasan N, King CM, Garrod DR, Thompson PJ, et al. On the 
potential significance of the enzymatic activity of mite allergens to immunogenicity. Clues to structure and 
  ENA-78 IS DEGRADED BY HDM EXTRACT DERIVED PROTEASES 
 
123 
function revealed by molecular characterization. Clinical and experimental allergy : journal of the British 
Society for Allergy and Clinical Immunology. 1997;27(1):10-21. 
16. Kauffman HF, Tamm M, Timmerman JA, Borger P. House dust mite major allergens Der p 1 and 
Der p 5 activate human airway-derived epithelial cells by protease-dependent and protease-independent 
mechanisms. Clinical and molecular allergy : CMA. 2006;4:5. 
17. Miglino N, Roth M, Tamm M, Borger P. House dust mite extract downregulates C/EBPalpha in 
asthmatic bronchial smooth muscle cells. The European respiratory journal : official journal of the European 
Society for Clinical Respiratory Physiology. 2011;38(1):50-8. 
18. Kauffman HF, Tomee JF, van de Riet MA, Timmerman AJ, Borger P. Protease-dependent activation 
of epithelial cells by fungal allergens leads to morphologic changes and cytokine production. The Journal of 
allergy and clinical immunology. 2000;105(6 Pt 1):1185-93. 
19. Leidal KG, Munson KL, Johnson MC, Denning GM. Metalloproteases from Pseudomonas 
aeruginosa degrade human RANTES, MCP-1, and ENA-78. Journal of interferon & cytokine research : the 
official journal of the International Society for Interferon and Cytokine Research. 2003;23(6):307-18. 
20. Johnson PR, Armour CL, Carey D, Black JL. Heparin and PGE2 inhibit DNA synthesis in human 
airway smooth muscle cells in culture. The American journal of physiology. 1995;269(4 Pt 1):L514-9. 
21. Johnson PR, Roth M, Tamm M, Hughes M, Ge Q, King G, et al. Airway smooth muscle cell 
proliferation is increased in asthma. American journal of respiratory and critical care medicine. 
2001;164(3):474-7. 
22. Seidel P, Roth M, Ge Q, Merfort I, S'Ng C T, Ammit AJ. IkappaBalpha glutathionylation and 
reduced histone H3 phosphorylation inhibit eotaxin and RANTES. The European respiratory journal : official 
journal of the European Society for Clinical Respiratory Physiology. 2011;38(6):1444-52. 
23. Fillmore RA, Nelson SE, Lausch RN, Oakes JE. Differential regulation of ENA-78 and GCP-2 gene 
expression in human corneal keratocytes and epithelial cells. Investigative ophthalmology & visual science. 
2003;44(8):3432-7. 
24. Henness S, van Thoor E, Ge Q, Armour CL, Hughes JM, Ammit AJ. IL-17A acts via p38 MAPK to 
increase stability of TNF-alpha-induced IL-8 mRNA in human ASM. American journal of physiology Lung 
cellular and molecular physiology. 2006;290(6):L1283-90. 
25. Strieter RM, Burdick MD, Mestas J, Gomperts B, Keane MP, Belperio JA. Cancer CXC chemokine 
networks and tumour angiogenesis. Eur J Cancer. 2006;42(6):768-78. 
26. Baggiolini M, Dewald B, Moser B. Interleukin-8 and related chemotactic cytokines--CXC and CC 
chemokines. Advances in immunology. 1994;55:97-179. 
27. Kikuchi S, Kikuchi I, Takaku Y, Kobayashi T, Hagiwara K, Kanazawa M, et al. Neutrophilic 
inflammation and CXC chemokines in patients with refractory asthma. International archives of allergy and 
immunology. 2009;149 Suppl 1:87-93. 
28. Nakagome K, Matsushita S, Nagata M. Neutrophilic inflammation in severe asthma. International 
archives of allergy and immunology. 2012;158 Suppl 1:96-102. 
29. Strieter RM, Chensue SW, Basha MA, Standiford TJ, Lynch JP, Baggiolini M, et al. Human alveolar 
macrophage gene expression of interleukin-8 by tumor necrosis factor-alpha, lipopolysaccharide, and 
interleukin-1 beta. American journal of respiratory cell and molecular biology. 1990;2(4):321-6. 
30. Walz A, Schmutz P, Mueller C, Schnyder-Candrian S. Regulation and function of the CXC 
chemokine ENA-78 in monocytes and its role in disease. Journal of leukocyte biology. 1997;62(5):604-11. 
ENA-78 IS DEGRADED BY HDM EXTRACT DERIVED PROTEASES   
 
124 
31. Walz A, Burgener R, Car B, Baggiolini M, Kunkel SL, Strieter RM. Structure and neutrophil-
activating properties of a novel inflammatory peptide (ENA-78) with homology to interleukin 8. The Journal 
of experimental medicine. 1991;174(6):1355-62. 
32. Imaizumi T, Albertine KH, Jicha DL, McIntyre TM, Prescott SM, Zimmerman GA. Human 
endothelial cells synthesize ENA-78: relationship to IL-8 and to signaling of PMN adhesion. American 
journal of respiratory cell and molecular biology. 1997;17(2):181-92. 
33. Schnyder-Candrian S, Walz A. Neutrophil-activating protein ENA-78 and IL-8 exhibit different 
patterns of expression in lipopolysaccharide- and cytokine-stimulated human monocytes. J Immunol. 
1997;158(8):3888-94. 
34. Thomas WR, Smith WA, Hales BJ, Mills KL, O'Brien RM. Characterization and immunobiology of 
house dust mite allergens. International archives of allergy and immunology. 2002;129(1):1-18. 
35. Song J, Wu C, Zhang X, Sorokin LM. In vivo processing of CXCL5 (LIX) by matrix 
metalloproteinase (MMP)-2 and MMP-9 promotes early neutrophil recruitment in IL-1beta-induced 
peritonitis. J Immunol. 2013;190(1):401-10. 
36. Mortier A, Loos T, Gouwy M, Ronsse I, Van Damme J, Proost P. Posttranslational modification of 
the NH2-terminal region of CXCL5 by proteases or peptidylarginine Deiminases (PAD) differently affects its 
biological activity. The Journal of biological chemistry. 2010;285(39):29750-9. 
37. Kay AB. The role of eosinophils in the pathogenesis of asthma. Trends in molecular medicine. 
2005;11(4):148-52. 
38. Kay AB, Phipps S, Robinson DS. A role for eosinophils in airway remodelling in asthma. Trends in 
immunology. 2004;25(9):477-82. 
39. Lemiere C, Ernst P, Olivenstein R, Yamauchi Y, Govindaraju K, Ludwig MS, et al. Airway 
inflammation assessed by invasive and noninvasive means in severe asthma: eosinophilic and 
noneosinophilic phenotypes. The Journal of allergy and clinical immunology. 2006;118(5):1033-9. 
40. Wenzel SE. Eosinophils in asthma--closing the loop or opening the door? The New England journal 
of medicine. 2009;360(10):1026-8. 
41. Bischof RJ, Snibson K, Shaw R, Meeusen EN. Induction of allergic inflammation in the lungs of 
sensitized sheep after local challenge with house dust mite. Clinical and experimental allergy : journal of the 
British Society for Allergy and Clinical Immunology. 2003;33(3):367-75. 
  KEY FINDINGS, CONCLUSIONS AND FUTURE PERSPECTIVES 
 
125 
Key findings, conclusions and future perspectives 
Key findings 
In the present thesis it has been demonstrated that human primary bronchial smooth muscle 
cells (BSMC) release factors, which have the potential to induce angiogenesis. Therefore 
BSMC are able to contribute to angiogenesis in asthma-associated airway wall remodeling. 
Three objectives have been answered in this thesis as follows: 
BSMC obtained from asthma patients exhibit a significantly increased angiogenic potential 
in an experimental in vitro inflammatory environment. The increased angiogenic potential 
of BSMC obtained from asthma patients was attributed to the release of ELR
+
 CXC-
chemokines and monitored by sprout outgrowth from endothelial cells (EC) spheroids. 
Blocking the corresponding receptor (CXCR2) abrogated the increased sprout outgrowth 
from EC spheroids induced by conditioned media (CM) of BSMC from asthma patients.  
Low oxygen concentration (hypoxia) has a severe impact on the proliferative capacities of 
BSMC. Reduction of oxygen in vitro significantly reduced BSMC proliferation. Although 
findings in a rat model of asthma suggested a direct correlation between low oxygen 
concentration and increased BSM mass, where moderate hypoxia increased the 
proliferation in BSMC, this could not be confirmed in human BSMC. However, low 
oxygen concentration induced the release of pro-inflammatory and pro-angiogenic 
mediators by BSMC. In contrast to the angiogenic capacity of BSMC under inflammatory 
conditions (described above), the major regulator of hypoxia-induced angiogenesis was 
VEGF.  
Incubation of BSMC with HDM extract did not have a direct effect on their potential to 
induce angiogenesis. The levels of several pro-inflammatory and pro-angiogenic proteins 
were unchanged in CM of HDM extract-stimulated BSMC. Nevertheless, it has been 
shown that ENA-78 levels in CM derived from HDM extract-stimulated BSMC were 
significantly decreased. Quantitative analysis of ENA-78 mRNA levels revealed that HDM 
extract only affected the ENA-78 protein levels. Further investigations suggested a 
proteasomal degradation of ENA-78 by proteases which were contained in the HDM 
extract. The ability of ENA-78, incubated with HDM extract, to induce neutrophil 
migration was reduced and might cause an altered composition of the inflammatory 
immune cells infiltrating the airways of asthma patients.  
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Conclusions 
This thesis provides experimental evidence that BSMC actively participate in angiogenesis 
and airway wall remodeling in asthma. Furthermore, BSMC-derived factors, which can 
induce angiogenesis under different conditions, were identified.  
Importantly, BSMC obtained from asthma patients released more of three angiogenic 
factors, ENA-78, GRO-α and IL-8, which all bind to the same receptor, CXCR2. Although 
immune cells and epithelial cells are regarded as the major sources of CXCR2-chemokines 
our findings showed, that BSMC are an additional source of ENA-78, GRO-α and IL-8. 
Elevated levels of GRO- and IL-8 in the BALF of asthmatics [1] have been reported as 
well as increased ENA-78 level in sputum of asthmatic children [2]. Using different 
stimuli, recent studies revealed that BSMC are a potential source for IL-8 and GRO- [3, 
4]. However, the release of the CXCR2 ligands in an experimental inflammatory 
environment (FCS stimulation) has never been described before. The blocking of the 
CXCR2 and the subsequent reduction of sprout outgrowth from EC spheroids confirmed 
the important role of these mediators in asthma-associated angiogenesis and their cellular 
source – the BSMC.  
The second objective was to investigate if hypoxia has a direct effect on BSMC 
hyperplasia. Hypoxia can be caused by decreased ventilation, airway obstruction, intra-
alveolar exudate, septal thickening by edema, inflammation, fibrosis, or damage of 
alveolar capillaries. These pathologies or their combination can reduce proper oxygenation 
[5]. Our findings show that moderate and severe hypoxia on one side led to decreased 
proliferation of BSMC, but on the other side increased the release of pro-inflammatory and 
pro-angiogenic mediators.  
The observation that low oxygen concentration led to reduced BSMC proliferation is 
contrary to an animal model. The rat model suggested hypoxia as a direct cause of BSMC 
hyperplasia by increasing proliferation [6]. Although we did not find evidence that hypoxia 
directly caused BSMC hyperplasia, we found an increased release of pro-inflammatory and 
pro-angiogenic mediators in CM obtained from BSMC. The effect of hypoxia on the 
release of other pro-inflammatory and pro-angiogenic mediators in the pathogenesis of 
asthma has been described before in humans and animal models [5, 7-13].  
The increase in BSM mass might cause locally restricted hypoxia. It has been 
demonstrated that hypoxia occurs during tissue expansion and organ growth [14, 15]. Here, 
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the increase of the tissue mass resulted in a higher oxygen demand and insufficient 
delivery, which caused temporal local hypoxia. This finding suggested that the increased 
BSM mass could have similar effects in the airways of asthma patients. Other mechanisms 
how hypoxia could be induced in the airways of asthmatics are: (i) inflammation resulting 
in increased oxygen consumption, or (ii) edema which has an impact on oxygen diffusion 
through the tissue, (iii) as well as basement membrane thickening, resulting in impaired 
diffusion. Together these physiological alterations might lead to locally restricted hypoxia 
and which activate the HIF cascade, similar to that described in systemic hypoxia [10].  
The connection of inflammation and angiogenesis has been noticed long ago [16], and it is 
now generally accepted that hypoxia and inflammation are inseparably intertwined with 
HIF-1 α as pivotal molecular mediator [9, 17-21]. However, to date, this interconnection 
has been studied mainly in the context of solid tumors [22-25].  
In this thesis it was demonstrated that hypoxic conditions significantly increased the 
release of VEGF by BSMC whereas CXCR2 ligands were the major mediators for 
inflammation-induced angiogenesis. VEGF is a crucial factor for BSMC induced 
angiogenesis under IL-1β and IL-13 stimulation [26]. Our finding that CXCR2 are 
important mediators in BSMC-mediated induction of angiogenesis provided an additional 
mechanism how angiogenesis in the asthmatic airway wall might be induced independently 
of VEGF. Furthermore this thesis provides evidence that the cellular microenvironment 
plays an important role in the induction of angiogenesis and the release of pro-angiogenic 
mediators. 
The third objective of the thesis was to study the effect of HDM extract on the angiogenic 
properties of BSMC. Studies in several model organisms (mice, sheep, primates) showed 
that HDM allergens increased vascularity of the lungs [27-30]. Studies from our group 
demonstrated that HDM extracts elicit several changes in BSMC. Proliferation and release 
of pro-inflammatory mediators were increased in HDM-stimulated BSMC [31]. HDM 
allergens therefore directly contribute to airway wall remodeling via a non-immune cell 
mediated mechanism. These data support earlier findings of Plopper et al. that HDM 
exerted its effect independently of the immune system via resident tissue-forming cells 
[32].  
Since we did not find a direct effect of HDM extract on the angiogenic potential of BSMC 
we speculate that the pro-angiogenic effects of these allergens might be mediated by 
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immune or endothelial cells, which have been shown to release angiogenic mediators upon 
stimulation with allergens [33], rather than by an altered release of angiogenic mediators 
from BSMC. One interesting finding of our studies was the down-regulation of the pro-
angiogenic chemokine ENA-78, which is involved in neutrophil recruitment, with 
unchanged mRNA levels. We showed that the down-regulation of ENA-78 was a 
secondary effect caused by proteases present in HDM extract. Data on neutrophil 
transmigration suggest a diminished migration of neutrophils towards a gradient of HDM 
extract-incubated ENA-78 compared to untreated ENA-78. In a physiological context the 
degradation of ENA-78 might influence the composition of inflammatory cells in the 
airways. 
The findings of my thesis add further evidence to the recently recognized role of tissue-
forming cells and in particular of BSMC to the pathogenesis of asthma. They elucidate the 
role of BSMC in inflammation-induced and hypoxia-induced angiogenesis in the asthmatic 
lung. 
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Future perspectives 
Changes in the microvasculature have various deleterious effects: the increased vasculature 
provides blood and oxygen supply to the excess number of tissue-forming cells and to the 
inflammatory infiltrates in the bronchial wall of asthma patients. Thereby, increased 
vascularization may promote airway wall remodeling. The thickening of the airway wall 
sub-epithelial cell layers, together with the edematous effects of increased numbers and 
size of blood vessels results is airway narrowing, the major long term complication of 
asthma [34]. Blood vessels are the primary portal for immune cells to infiltrate tissues and 
the increased number of blood vessels in the airway wall of asthma patients might lead to 
exaggerated inflammation. [35]. There is evidence that badly controlled asthma results in 
an increase in inflammatory cells, which are entering the airway tissue via ancillary blood 
vessels [36]. Therefore, endothelial cells as well as BSMC might be promising new targets 
to reduce airway wall remodeling and asthma symptoms. 
A very important aim for future research is the better understanding of the triggers that 
cause the release of angiogenic mediators from BSMC and a deeper knowledge on the 
physiological microenvironment of BSMC in the lungs of asthma patients. We clearly 
showed that different stimuli lead to altered release of angiogenic mediators by BSMC. In 
experiments mimicking inflammation chemokines of the CXC-family were the main 
inducers of angiogenic effects.  
BSMC under hypoxic conditions induced angiogenesis mainly by the release of VEGF. 
Increased VEGF level in the airways of patients with asthma and in patients with 
eosinophilic bronchitis have been reported [37]. This suggests that VEGF is an important, 
but not sufficient factor in regulation angiogenesis in airway wall remodeling in asthma. It 
is of interest to further assess how the different pathways might be linked and if there is a 
common target for future therapeutic interventions. This is of course a very ambitious aim, 
as the process of angiogenesis is very complex and involves multiple factors with 
complementary and coordinated roles. 
Another important question might arise from the source of endothelial cells building the 
new vessels. In a mouse model of asthma, it has been shown that endothelial precursor 
cells (EPC) from the bone marrow are recruited to the lungs via CXCR2 ligands [38]. 
Furthermore, it has been shown that in sputum from asthmatics the number of EPC is 
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increased. It would be of interest to know, if BSMC are involved in this process, because 
they are an important source of CXCR2 as shown in the present thesis.  
The beneficial effect of bronchial thermoplasty in reducing asthma symptoms [39-43], 
together with the finding that BSMC produce factors that aggravate the airway wall 
remodeling process [44, 45], suggest a pivotal role of BSMC in asthma pathogenesis. 
Therefore, the development of (inhaled) anti-angiogenic agents might be an interesting 
new strategy to reduce BSM mass.  
In conclusion, there is a fundamental demand to develop new treatment options or curative 
drugs to improve the quality of life of asthma patients. In cancer, several anti-angiogenic 
drugs have been developed and are currently in use or are tested in clinical trials to treat 
tumors. Angiogenesis in asthma has only recently come into the focus of researchers and a 
better understanding of the mechanisms contributing to asthma pathology as well as 
elucidation of the interconnection of the multiple processes involved may provide the basis 
for the use of such treatments in asthma therapy.    
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Extended Methods 
Cell Biology 
Primary bronchial smooth muscle cells - Cryopreservation 
BSMC were washed with Dulbecco's phosphate-buffered saline (DPBS) and trypsinzed 
(3 min, 37°C). After centrifugation (5 min, 1000 rpm) 1x10
6
 BSMC per cryostock were 
resuspended in 0.8 ml CyroMaxx S (PAA, GE Healthcare, Glattbrugg, Switzerland) and 
cooled down in a “Mr. Frosty” freezing container (Nalgene, Thermo-Scientific, Lausanne, 
Switzerland) in a -80°C freezer overnight. For long-term storage cells were transferred to 
liquid nitrogen. 
Primary bronchial smooth muscle cells - Isolation and Cultivation 
Human BSMC were obtained from endobronchial biopsies of asthmatic subjects. BSMC 
from control subjects were obtained from endobronchial biopsies from non-asthmatic 
patients or from macroscopically normal/healthy tissue parts of lungs from patients 
undergoing therapeutic partial lung resection. The study protocol was approved by the 
local ethical committee (Ethikkommission beider Basel, EK 05/06) and all patients gave 
written informed consent.  
Isolation of BSMC was performed as described earlier [1, 2] with some modifications. 
Muscle bundles from endobronchial biopsies or from bronchi (diameter 5-10 mm) 
dissected from tissue sections were uncovered from the overlying epithelial cell layer 
under a binocular microscope. Smooth muscle bundles were dissected from the 
parenchyma, detached in smaller pieces and placed into 25 cm
2
 tissue culture flasks (BD 
Biosciences, Allschwil, Switzerland) in Dulbecco`s modified Eagle`s medium (DMEM) 
containing GlutaMax-I 4.5 g/l glucose (Gibco
®
, Bioconcept, Allschwil, Switzerland), 5% 
FCS, 1x antibiotics-antimycotics, and 1x modified Eagle`s medium vitamin mix 
(Invitrogen, Lubio, Luzern, Switzerland) and grown under normoxic conditions (20% O2, 
5% CO2, 37 °C). Cells reached confluency after 3-6 weeks and were then passaged to 75 
cm
2
 cell culture flasks. To confirm the cell type immunostaining against smooth muscle 
myosin, smooth muscle actin and fibronectin were performed [3]. Cells were cultured in 
Roswell Park Memorial Institute medium (RPMI) 1640 (Gibco
®
, Bioconcept, Allschwil, 
Switzerland) supplemented with 5% FCS, 1x antibiotics-antimycotics, and 1x modified 
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Eagle`s medium vitamin mix (BSMC-GM) and subcultured in ratios 1:2 – 1:4 upon 
confluency. 
Primary bronchial smooth muscle cells – Stimulation and treatment 
Prior to stimulation all cells were growth arrested for 24 h, in BSMC basal medium 
(BSMC-BM): RPMI 1640 containing 0.1% FCS, 1x antibiotics-antimycotics and 1x 
modified Eagle`s medium vitamin mix.  
To determine the angiogenic potential of BSMC and to mimic an inflammatory 
environment BSMC were stimulated with 5% FCS, or kept in serum-free medium as a 
control. These media were used in the angiogenesis array, in the 3D in vitro angiogenesis 
assay, and in ELISA to measure cytokine secretion.  
To determine the effect of house dust mite (HDM) extract (ALK-Abelló, Hørsholm, 
Danmark) on cytokine release and angiogenic properties HDM extract was dissolved in 
BSMC-BM and passed through a sterile filter (0.22 µm). BSMC were treated with either 
2 µg/ml, or 10 µg/ml, or no HDM extract for 24 h and 72 h in the presence and absence of 
5% FCS. Colistin (Roth, Arlesheim, Switzerland) in a concentration of 10 ng/ml was 
added to block possible effects of LPS-contaminations in the HDM extract.  
Hypoxia conditioned medium (CM) was obtained by using a Heracell 150i CO2 incubator 
(Thermo-Scientific, Lausanne, Switzerland) set to hypoxic conditions (1% O2 or 5% O2, 
5% CO2, 37 °C). Cells were incubated for 72 h.  
All CM were harvested, spun down to remove cell fragments and kept at -80°C. 
HMEC-1 cells – Cultivation 
The human cell line HMEC-1 (human microvascular endothelial cell line-1) is an 
immortalized cell line. It was generated from the transfection of human dermal 
microvascular cells with a PBR-322-based plasmid coding for the large T antigen of the 
simian virus 40 [4].  In angiogenesis related to asthma microvessels are formed first. 
Therefore, it is reasonable to use microvascular cells preferably to endothelial cell of 
large vessel. Another advantage of the HMEC-1 cell line is their capacity to divide and 
maintain the EC phenotype [4]. The HMEC-1 cells used in the experiments described 
were a generous gift from Prof. Dr. Thérèse Resink.  
HMEC-1 cells were cryopreserved (analogous to cryopreservation protocol for BSMC) 
and thawed upon requirement. They were cultured in EC growth medium (ECGM)/10% 
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FCS (Provitro, Bioconcept, Allschwil, Switzerland) and subcultured in ratios 1:5 – 1:10 
as required.  
The 3D in vitro angiogenesis assay 
The 3D in vitro angiogenesis assay was used to determine the angiogenic potential of CM 
derived from BSMC. The EC sprouting assay is a standard procedure to study 
angiogenesis [5-8] and has been performed as previously described [8] with some 
modifications. 
 Preparation of methylcellulose: 
6 mg of methylcellulose with a viscosity of 4,000 cP (Sigma-Aldrich, Buchs, 
Switzerland) were dissolved in 250 ml pre-warmed (60°C) endothelial cell basal medium 
(ECBM) (Provitro, Bioconcept, Allschwil, Switzerland) without FCS or supplement (1 h, 
magnetic stirrer). Another 150 ml of ECBM were added and the solution was stirred for 
15 min. The solution was centrifuged for 20 min at 3000 rpm and the clear, homogenous 
supernatant was transferred into new tubes and store at 4°C until used for spheroid 
formation. 
 Preparation of fibrinogen solution 
Fibrinogen (Sigma-Aldrich, Buchs, Switzerland) was vacuum dried in a vacuum 
concentrator (20 min, RT) prior to weighing. 8 mg/ml of fibrinogen have been dissolved 
in ECBM (no FCS, no supplements) and passed through a sterile filter (0.22 µm). 
Fibrinogen solution was kept on ice to avoid polymerization. 
 Experimental procedure: 
To prepare EC spheroids, droplets of 25 µl of HMEC-1 cell suspension (c = 20000 
cells/ml, in ECGM/10% FCS containing 20% methylcellulose) were seeded in the lid of a 
15 cm cell culture dish. Droplets were incubated inverted (hanging drops), overnight in a 
humidified incubator, as described elsewhere [9]. This procedure forces the HMEC-1 
cells to form coherent 3 D-aggregates, called “spheroids”.. After the incubation droplets 
were harvested and centrifuged (800 rpm, 10 min), the supernatant was removed and 
175 µl of fibrinogen solution and 150 µl of ECGM/10% FCS containing 20% 
methylcellulose were added. To induce polymerization of fibrinogen 18 µl of thrombin 
solution (c=10 U/ml in DPBS; Sigma-Aldrich, Buchs, Switzerland) was added, and 
HMEC-1 spheroid suspension was transferred into a pre-warmed (37°C) 48-well plate. 
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One gel contains of at least 10 spheroids. After polymerization (30 min – 1 h), the gels 
were overlaid with 400 µl of the to-be-tested medium. For all experiments with CM gels 
were incubated with a 1:1 mixture of CM and ECGM/2% FCS. In experiments with 
chemical inhibitors and neutralizing antibodies these were added to the gels and to the 
medium mixture in the indicated concentrations. In experiments using a VEGF 
neutralizing antibody (R&D, Abingdon, UK) CM were pre-treated with 0.2 µg/ml VEGF 
antibody for 1 h before adding the CM to the gels. In experiments using SB 265610 gels 
were overlaid with medium containing SB 265610 at a concentration of 1, 5, 50 nM for 
45 min prior to stimulation with CM. After 24-32h of experimental incubation HMEC-1 
spheroids were fixed in-gel with 4% formaldehyde in DPBS (1 h, RT). Gels were washed 
(3x DPBS, 1 h) and stained overnight with 0.5 µg/ml TRITC phalloidin (Sigma-Aldrich, 
Buchs, Switzerland) in DPBS. For analysis images of each spheroid were taken (Olympus 
IX50 inverted microscope equipped with Color View II camera, Olympus Schweiz 
GmbH, Le Mont-sur-Lausanne, Switzerland) and the length of the 10 longest outgrowing 
capillary-like structures from each spheroid was measured (analySis software, Soft 
Imaging Systems GmbH) and expressed as the total length of sprouts per spheroid. 
Viability and proliferation assays 
BSMC were seeded at a density of 5x10
5
 cells/well in a 12-well plate in BSMC-GM and 
grown for 24 h. After 24 h of serum-deprivation (BSMC-BM) cells were stimulated with 
5% FCS and grown for 72h in humidified atmosphere incubators with 1%, 5% or 
21% O2. Wells were washed with DPBS, trypsinized and counted in a mechanical cell 
counter (Beckman Coulter particle counter Z1, Nyon, Switzerland). Viability was 
assessed by Trypan blue staining and manual cell counting (Neubauer chamber). 
HMEC-1 cells were seeded at 7.5x10
4 
cells/well in 48-well plates, grown for 24 h in 
ECGM/10% FCS, serum-deprived for 24 h (ECBM) and then further cultured in 
ECGM/10% FCS without or with inclusion of SB 265610. Viability was examined after 
24 h by Trypan blue staining and manual cell counting using a Neubauer chamber. Cell 
numbers were determined after 48 h by enzymatic disaggregation using a Beckman 
Coulter particle counter Z1 (Nyon, Switzerland). Experiments were performed in 
duplicates and the cell suspension of each well was at least counted twice.  
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Isolation of neutrophils 
Fresh anticoagulated blood from healthy donors was used to purify neutrophils by 
discontinuous density gradient centrifugation Polymorphprep
™
 medium (Axis-Shield, 
Axon Lab, Baden, Switzerland). 5 ml of separation medium was carefully overlaid with 
5 ml of citrate-blood and centrifuged at 500 rcf for 35 min. The layer containing 
polymorphonuclear cells was harvest into a 15 ml tube. One washing step (10 ml, DPBS 
(w/o Ca
2+
, Mg
2+
), 500 rcf, 10 min) was performed and then remaining erythrocytes were 
lysed using 2 ml of RBC Lysis medium (AppliChem, Axon Lab, Baden, Switzerland). 
Following a second washing step (10 ml, DPBS (w/o Ca
2+
, Mg
2+
), 300 rcf, 5 min) the cell 
pellet was resuspended in 1 ml of DPBS, cell number was determined, and 30 µl of cell 
suspension were used for Differential Quik staining to confirm purity and identity of 
isolated cells. 
Chemotaxis assay 
Chemotaxis was assessed using 96-well Boyden chamber (Neuroprobe, Gaithersburg, 
USA) The lower compartment of the 96-wells chambers were filled with 100 ng/ml 
recombinant ENA-78, 10 ng/ml recombinant ENA-78 in RPMI (treated for 24 with and 
without 10 µg/ml HDM extract), with 100 ng/ml recombinant ENA-78, with 10µg/ml 
HDM extract in RPMI or RPMI alone and then covered with a 5 μm pore-sized 
polycarbonate filter (Neuroprobe, Gaithersburg, USA). Next, 200 μl of neutrophil 
suspension (2x10
6
 cells/ml) was added to the upper compartments. After 2 h of incubation 
(37°C, 5% CO2) the upper compartment was removed, cells on the upper side of the filter 
were wiped with a tissue and the filter was fixed and stained with Differential Quik 
Staining Kit (Brunschwig, Basel, Switzerland). The membrane was scanned with a 
desktop scanner, and the intensity of spots was analyzed using Image J software. 
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Tissue sectioning and staining 
Milligan’s Trichrome Staining 
Airway tissue were fixed in 4% phosphate-buffered formalin (pH 7.2) and embedded in 
paraffin. Sections of 3 µm thickness were cut using a Shandon Finesse 325 (Thermo 
Scientific, Victoria, Australia) microtome and mounted on Superfrost Plus microscope 
slides (Lomb Scientific, Taren Point, Australia) to be used for immunohistochemical 
analysis. 
Tissue sections were de-paraffinized in xylene (MP Biomedicals, Santa Ana, CA) (2x, 
10 min) and rehydrated through graded alcohol (2x 100%, 2x 95% and 70% Ethanol; 2 
min each) and washed in ddH2O for at least 2 min.  
Staining procedure: 
  Weigert’s haematoxylin for 5 min, rinsed with tab water  
 Scott’s solution, rinsed with tab water  
 Mordant solution (74.6 mM Potassium dichromate, 250 mM Hydrochloric acid in 
23% Ethanol) for 5-7 min, rinsed with ddH2O  
 0.1% acid fuschin solution for 5-8 min, rinsed with ddH2O 
  1% phosphomolybdic acid solution for 1-5 min 
 2% Orange G solution for 5-10 min, rinsed with ddH2O 
 1% acetic acid solution for 2 min 
 1% fast green solution for 5-10 min  
 1% acetic acid solution for 3 min.  
The sections were then dehydrated through graded alcohol up to 95% ethanol and 
coverslipped with organic mounting media DPX (Asia Pacific Specialty Chemicals, 
Australia). Images were taken with an Olympus BX60 microscope  equipped with an 
attached DP71 camera (Olympus, Hamburg, Germany) with manual light exposure and 
‘one push’ white balance on a background region. Images were kindly provided by Mr. 
Gavin Tjin, Woolcock Institute of Medical Research, Australia. 
Haematoxylin-Eosin Staining 
Endobronchial biopsies of the airway mucosa were snap frozen in optimal cutting 
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temperature (OCT) medium (Tissue-Tek, Sakura Finetechnical, Tokyo, Japan) on a cork 
disc by immersion in a beaker of isopentane (2-methylbutane, HPLC grade, Sigma-
Aldrich, Castle Hill, Australia) suspended in a flask of liquid nitrogen and stored at -80ºC 
for later sectioning. Sections of 7 µm thickness were cut with a cryostat (Shandon 
Cryotome 620E, Thermo Scientific, Victoria, Australia) at a temperature of -18ºC. The 
frozen sections were air dried at room temperature, fixed in 50% acetone/50% methanol 
for 90 s and stained with Harris’s haematoxylin (5 min) and alcoholic eosin (2 min) 
(Fronine Laboratory Supplies, Taren Point, Australia). Light microscopic photographic 
images (Olympus AX70 microscope, DP50 camera) at 60x power were recorded. 
Cryosectioning, fixation, staining and photography were performed by Dr. Jane Radford 
(with the assistance of Barbara Hernandez) in the Histopathology Laboratory, Faculty of 
Medicine, The University of Sydney. 
Differential Quik staining 
The Differential Quik Stain Kit is a modified Giemsa staining and was used to confirm 
purity of neutrophil isolations and to stain the migrated neutrophils in the chemotaxis 
assay. For differential staining cell suspension smears on glass slides were used. The 
staining procedure was performed as recommended by the manufacturer. After airdrying 
the glass slides, cells were fixed for 10 s in solution A, followed by 5 dips in solution B 
and 5 dips in solution C and rinsing the slide with tab water. After airdrying the glass slide 
were dipped in Xylene and cover slipped. The staining of the polycarbonate-filters of the 
chemotaxis assay have been stained as follows: 
 To remove non-migrated neutrophils from the upper side of the filter the filter was gently 
wiped with a tissue. The filter was then transferred to the fixative solution (Solution A) 
for 2 min, incubated for 45 s in Solution B followed by 45 s incubation in solution C. The 
filter was washed with ddH2O and airdried. 
Immunocytochemistry 
HMEC-1 cells were grown to 70% confluency, washed with DPBS, and fixed in 4% 
formaldehyde for 20 min. Cells were permeabelized using 0.5% Triton X-100/1% BSA in 
DPBS. After blocking with 5% BSA in DPBS for 1 h cells were incubated with mouse 
anti- CXCR2 (Abcam, Lucerna-Chem, Luzern, Switzerland) or mouse IgG (DAKO, Baar, 
Switzerland) as a negative control, for 2 h at RT. Cells were washed 3x with 
DPBS/0.05%Triton X-100 (5 min) and incubated with goat anti-mouse IgG FITC-
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conjugated (Southern Biotech, Lucerna-Chem, Luzern, Switzerland) for 1 h. Cells were 
washed 4x with DPBS (5 min) and addition of 200 ng/ml Hoechst 33342 in the second 
washing step. Images were taken with an Olympus IX50 inverted microscope equipped 
with Color View II camera (Olympus Schweiz GmbH, Le Mont-sur-Lausanne, 
Switzerland). 
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Molecular Biology and Biochemistry 
SDS-PAGE and Western Blotting 
Cells were lysed using 5x loading buffer (Table 2). All analyzed proteins were size-
fractioned on precast 4-20% Tris-HEPES gels (Pierce, Thermo-Scientific, Lausanne, 
Switzerland). Gelelectrophoresis was performed in a Mini Protean Tetra Cell
®
 (BioRad, 
Cressier, Switzerland) in HEPES-running buffer (Pierce, Thermo-Scientific, Lausanne, 
Switzerland) for 50 min at 100 V. Gels were the subjected to an overnight transfer at 50°C 
to 0.45 µm pore size nitrocellulose membranes (BioRad, Cressier, Switzerland). This 
transfer uses diffusion of the proteins into the membrane and therefore two membranes 
are used, one on each side of the Tris-HEPES-Gel. Detection of α-tubulin, Cyclin E, 
Cyclin D, CXCR2, HIF1-α, and PCNA was performed as follows: 
 Detection of α-tubulin, Cyclin E, Cyclin D, PCNA  
The membrane was blocked with 3% BSA in Tris buffered saline containing 1% Tween-
20 (TBST) for 30 min. Primary antibodies were applied in TBST with 1% BSA for 2 h 
(1 h for α-tubulin) at RT. Membranes were washed 3x in TBST for 10 min. Secondary 
HRP-coupled antibodies against the corresponding species of the primary antibody were 
applied in TBST for 1 h (30 min for α-tubulin) at RT.  
Antibodies were purchased from Santa Cruz, Lucerna-Chem, Luzern, Switzerland.  
 Detection of HIF1-α  
The membrane was blocked for 1h with 5% BSA in TBST at RT and incubation with 
primary antibody was in 5% BSA in TBST at 4°C overnight. After 3x wash (10 min) 
TBST secondary antibodies were applied for 2 h at RT in 5% milk powder (BioRad, 
Cressier, Switzerland) in TBST. 
Antibodies were purchased from Cell Signaling Technologies, Bioconcept, Allschwil, 
Switzerland. 
 Detection of CXCR2 
The membrane was blocked for 1 h with 4% BSA in TBST at RT and incubation with 
primary antibody was in 1% BSA in TBST at 4°C overnight. After 3x wash (10 min) 
TBST secondary antibodies were applied for 1 h at RT in TBST. 
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Antibodies were purchased from Abcam (CXCR2) and Santa Cruz (HRP-conjugated 
secondary antibody)(Luzerna-Chem, Luzern, Switzerland). 
After 3x washing for 10 min in TBST membranes were incubated with SuperSignal
®
 
Western Pico Chemiluminescent Substrate (Pierce, Thermo-Scientific, Lausanne, 
Switzerland) for 5 min. Signal was detected on Fujifilm Super RX X-ray films (Lucerna-
Chem, Luzern, Switzerland) and developed in a Curix60 film-processor (Agfa, 
Dübendorf, Switzerland) 
Table 2: Buffers used in SDS-PAGE and Western Blotting. All chemicals were purchased from Sigma 
Aldrich, Buchs, Switzerland. 
Buffer chemical Volume/amount 
5x Loading buffer 0.5 M Tris pH 6.8 
Glycerol 
20% SDS 
β-mercaptoethanol 
1% bromphenolblue 
ddH2O 
 
2 ml 
3.2 ml 
1.6 ml 
0.8 ml 
1.6 ml 
6.8 ml 
TBST 0.5 M Tris pH 8 
5 M NaCl 
10% Tween 20 
add ddH2O to 1 l 
20 ml 
30 ml 
10 ml 
Transfer buffer 1 M Tris pH 7.5 
0.5 M EDTA 
5 M NaCl 
1 M DDT 
add ddH2O to 2 l 
20 ml 
8 ml 
20 ml 
200 µl 
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RT-PCR 
CXCR2 
HMEC-1 cells were plated in a 25 cm
2
 cell culture flask and grown to confluency. Cells 
were washed 2x with DPBS and total RNA was isolated using RNeasy Mini kit (Qiagen, 
Hombrechtikon, Switzerland) according to the manufacturer`s instructions. RNA 
concentration was determined by spectroscopy (NanoDrop, Witec, Luzern, Switzerland). 
First strand DNA was synthesized with m-MLV Reverse Transcriptase (from 5 µg of total 
RNA). Following reverse transcription cDNA was subjected to amplification with 
HotStarTaq Plus DNA polymerase (Qiagen, Hombrechtikon, Switzerland) using the 
following primers: forward 5`- CAG TTA CAG CTC TAC CCT GCC – 3, reverse 5` -
 CCA GGA GCA AGG ACA GAC CCC – 3 generating a 451 bp spanning fragment. PCR 
conditions were: 5 min 95°C; 30x: 30 sec 98°C, 30 sec 58°C, 1 min 72°C; 10 min 71°C. 
PCR products were size-fractioned on a 1% agarose gel, stained with ethidium bromide 
and visualized under UV light. 
ENA-78 & GAPDH 
BSMC were grown to confluency in 75 cm
2
 cell culture flasks, serum deprived for 24 h 
and stimulated with 20 µg/ml HDM extract for 6 h. Total RNA was isolated at t = 0 h and 
t = 6 h using Trizol reagent according to the manufacturer`s instructions. RNA 
concentration was determined by spectroscopy (NanoDrop, Witec, Luzern, Switzerland). 
First strand DNA was synthesized with m-MLV Reverse Transcriptase (from 5 µg of total 
RNA). Following reverse transcription cDNA was subjected to amplification with 
HotStarTaq Plus DNA polymerase (Qiagen, Hombrechtikon, Switzerland) using the 
following primers: ENA-78 forward 5’-ATC TCC GCT CCT CCA CCC AGT-3’ and 
ENA-78 reverse 5’-TTC TTG TCT TCC CTG GGT-3’ generated a PCR fragment 
spanning 493 bp and the primers GAPDH forward 5’-
CCA AAG GGT CAT CAT CTC TGC-3’ and GAPDH reverse 5’-
ATT TGG CAG GTT TTT CTA-3’ generating a PCR fragment spanning 417 bp. PCR 
conditions were: 5 min 95°C; 25x: 30 sec 98°C, 30 sec 58°C, 1 min 72°C; 10 min 71°C. 
PCR products were size-fractioned on a 1% agarose gel, stained with ethidium bromide 
and visualized under UV light. Densitometric analysis of mRNA expression was 
performed using Image J software and normalized to GAPDH. 
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Enzyme-linked Immunosorbent assay 
The presence ad concentration of angiogenic proteins in CM of BSMC were analyzed in 
duplicates by ELISA according to the manufacturer´s protocol. For each experiment a 
new standard curve was generated according to the manufacturer`s recommendations. 
Detection range and used dilutions of the CM are displayed in Table 3: 
Table 3: Standard curves and dilutions for commercial available ELISA kits 
 Detection range and standard curve Dilution factor 
ENA-78 15.6-1000 pg/ml, 2-fold dilution 5  
GRO-α 31.3-2000 pg/ml, 2-fold dilution 10 
IL-6 4.7-600 pg/ml, 2-fold dilution 30 to 50 
IL-8 (Anibiotech) 3.9-125 pg/ml, 2-fold dilution 25 
IL-8 (R&D) 31.3-2000 pg/ml, 2-fold dilution 8 
VEGF 31.3-2000 pg/ml, 2-fold dilution 1 
. 
IL-8 ELISA kits were purchased from Anibiotech (Vantaa, Finland) and from R&D 
(Abingdon, UK). ENA-78, GRO-α, IL-6 and VEGF ELISA kits were purchased from 
R&D (Abingdon, UK). 
Angiogenesis array 
The commercially available angiogenesis array G1 (Raybiotech, Lucerna-Chem, Luzern, 
Switzerland) was performed according to the manufacturer`s instructions. Undiluted CM 
from BSMC cells was applied to the array. The incubation with CM and with the 
secondary antibody cocktail (Cy3-labled) were performed at 4°C overnight. The 
manufacturer`s did not recommend to use FCS containing CM. Control experiments were 
performed to test the influence of FCS on the results by using RPMI 1640 without or with 
5% FCS as negative controls. Experiments revealed no interference of FCS with the 
array.  
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Cy3-fluoresence was measures with a NimbleGen MS 200 microarray Scanner (Roche, 
Basel, Switzerland) at a resolution of 10 µm and intensity was analyzed with AIDA 
software (Raytest, Straubenhardt, Germany). Afterwards slides were kept at -20°C. 
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